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ABSTRACT 
The processes of a human somatic cell are very complex with various genetic 
mechanisms governing its fate. Such cells undergo various genetic mutations, which 
translate to the genetic aberrations that we see in cancer. There are more than 100 types 
of cancer, each having many more subtypes with aberrations being unique to each. In the 
past two decades, the widespread application of high-throughput genomic technologies, 
such as micro-arrays and next-generation sequencing, has led to the revelation of many 
such aberrations. Known types and subtypes can be readily identified using gene-
expression profiling and more importantly, high-throughput genomic datasets have 
helped identify novel sub-types with distinct signatures. Recent studies showing usage of 
gene-expression profiling in clinical decision making in breast cancer patients underscore 
the utility of high-throughput datasets. Beyond prognosis, understanding the underlying 
cellular processes is essential for effective cancer treatment. Various high-throughput 
techniques are now available to look at a particular aspect of a genetic mechanism in 
cancer tissue. To look at these mechanisms individually is akin to looking at a broken 
watch; taking apart each of its parts, looking at them individually and finally making a 
list of all the faulty ones. Integrative approaches are needed to transform one-dimensional 
cancer signatures into multi-dimensional interaction and regulatory networks, 
consequently bettering our understanding of cellular processes in cancer. Here, I attempt 
to (i) address ways to effectively identify high quality variants when multiple assays on 
the same sample samples are available through two novel tools, snpSniffer and NGSPE; 
(ii) glean new biological insight into multiple myeloma through two novel integrative 
analysis approaches making use of disparate high-throughput datasets. While these 
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methods focus on multiple myeloma datasets, the informatics approaches are applicable 
to all cancer datasets and will thus help advance cancer genomics. 
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CHAPTER 1
INTRODUCTION 
1.1. Advances in sequencing technology 
In the past two decades, the acquisition of new knowledge in genetics has moved 
at an unprecedented pace. More precisely the rate of data generation has doubled every 
two years at a pace equivalent to Moore’s law(Mardis, 2008). The sequencing of DNA 
started off as a methodology description in a publication by Fred Sanger and Alan R. 
Coulson in 1977(Sanger, 1977). What initially started off as a laboratory pursuit to 
decipher genetic code of individual genes has completely changed the face of genetics 
today(Schuster, 2007).  The single most important event that enabled this transformation 
using such sequencing technology was the Human Genome Project (HGP). With the goal 
of fully deciphering human genetic code, HGP used numerous capillary based “factory-
like” sequencing centers which parallelized the processes utilizing hundreds of 
sequencing instruments(Schuster, 2007). 
The successful completion of the HGP only fueled genomic research with the 
appearance of 454 sequencing by synthesis instruments in 2004(Mardis, 2008; Margulies, 
et al., 2005). This technology further parallelized sequencing ability 50 fold at only one-
sixth the cost of capillary-based sequencers initially used for the HGP(Schuster, 2007). 
The research community’s initial skepticism of adopting 454s due to their high 
homopolymer error rate and short read length was answered by the development of a 
second wave of sequencing instruments such as the Roche’s genome sequencer, 
Illumina’s Solexa sequencer and the SOLiD sequencers(Schuster, 2007). Alternative 
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technologies, commonly called microarrays, were used in the late 1990s to characterize 
genotypes by employing hybridization to chips that utilized sequence specific 
probes(Brown, et al., 2001; Schena, et al., 1995). However, de novo sequencing has 
become the mainstay in genetics today.  
 
Instrument Sequencing  Chemistry 
Read Length 
(bp) 
Data per 
day 
Launch 
Year 
ABI 3730 Sanger Method 750-1100 1Mb 1990 
Roche 454 Pyrosequencing 250-400 ~320 Mb 2004 
Solexa Genome 
Analyzer Reverse Terminator 35-175 ~350 Mb 2006 
ABI SOLiD Ligation Sequencing ~35 ~600 Mb 2007 
Pacific Biosciences 
RS 
Single molecule 
realtime DNA 
sequencing 
~1000 -- 2010 
HiSeq 2500 Reverse Terminator ~150 ~25 Gb 2012 
Table 1:Shows increase of data generated per day of various commonly used sequencing 
instruments used since the Human Genome Project. 
 
Today Illumina’s HiSeq is the most commonly used sequencing instrument on the 
market, and can produce up to 90Gb sequencing data per day. The read lengths of the 
initial version of this technology, which were about 35 bp, have also increased 
significantly to today’s ~150 bp reads. This increase in read length, along with higher 
throughput at much reduced costs, have made the sequencing technology accessible to 
individual labs. 
Initially, this accessibility to sequencing technologies was widely successful in 
identifying associative genes in monogenic diseases. The basis for the success in 
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monogenic diseases has been in identifying associative Single Nucleotide Polymorphisms 
(SNPs) using high-throughput technologies. These studies focused on identifying non-
synonymous mutations uniquely in the cases, as opposed to controls that contributed to 
aberrant translation of amino acids that greatly increased the risk for a specific disease of 
interest(Hardy and Singleton, 2009). These initial studies followed the common disease-
common variant hypothesis to identify associative SNPs in Mendelian disorders(Manolio, 
et al., 2009). One such success story is the identification of risk allele mutations in the 
Complement Factor H(CFH) highly associative with Age-Related Macular Degeneration 
phenotype(Klein, et al., 2005). Another such success was the identification of deleterious 
mutations in DHODH in Millers Syndrome using exome sequencing(Ng, et al., 2010).  
Various other Genome Wide Association Studies (GWAS) were able to identify 
associative SNPs and genes in Mendelian disorders. However, such studies are often 
limited in their ability to identify biologically relevant genes in complex disorders. This is 
due to their low power(Manolio, et al., 2009) and the inability of such studies to look at 
other mechanisms beyond SNPs or mechanisms in conjunction with SNPs that contribute 
to the disease phenotype in complex disorders such as Type 2 Diabetes (T2D) and cancer. 
Moreover, though useful in identifying associative SNPs, GWAS seldom provide a target 
that can be used to cure aberrant phenotypes. 
Thankfully, sequencing technology improvements spanned beyond higher 
throughput and lower costs. There have been many advances in the type of assays that 
can be sequenced, giving researchers the opportunity to examine different types of 
genetic aberrations in the cell.  For example, Whole Genome Sequencing (WGS) today 
enables genome-wide detection of point mutations, copy number aberrations (CNA) and 
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structural rearrangements. Whole Exome Sequencing (WES) enables identification of 
variants in the coding sequences and copy number variations at a fraction of the cost 
compared to whole genome sequencing. Messenger RNA (mRNA) sequencing enabled 
researchers to characterize and quantify gene expression measurement across all the 
transcribed regions in a given sample. Small RNA sequencing provided researchers the 
ability to quantify small non-coding RNAs, commonly called miRNA. MiRNA were 
reported to have a regulatory influence on genes ranging from copy number regulation in 
bacteria to X-chromosome inactivation in humans(Del Solar and Espinosa, 2000; 
Mlynarczyk and Panning, 2000). Whole transcriptome sequencing has allowed the 
investigation of mRNA and Long Non-Coding RNA(lncRNA)(Prensner and Chinnaiyan, 
2011) previously implicated in tumorigenesis and cancer progression(Huarte and Rinn, 
2010; Prensner, et al., 2011). 
Similarly, numerous assays were also developed to study the epigenome. 
Chromatin Immunoprecipitation Sequencing (ChIP-Seq) technique lets one examine the 
histone modifications genome-wide in a model of interest. Identifying where 
transcription factors bind and how they influence transcription and consequently 
phenotype in a model of interest is also facilitated through ChIP-Seq. Methyl-Seq 
similarly enables one to look at the methylation patterns across the genome. Though the 
above outlined assays are the most commonly used, many more assays which are less 
common are used to probe into the molecular processes of the cell in ways that were 
never before possible. Examples of the less commonly used assays are RIP-Seq, CLIP-
Seq and FAIRE-Seq among the many currently available techniques. 
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These improvements in technology are providing answers that SNPs alone in the 
initial sequencing studies could not. Two or more assays together on a single sample let 
us examine how molecular mechanisms in concert contribute to certain phenotypes in 
complex diseases such as cancer.  
 
1.2. Cancer as a complex disease: 
Cancer has more than 100 disease types and even more diverse subtypes. It is 
characterized by unrestrained proliferation of cells. Cancer cells invade beyond the 
tumorigenesis site and metastasize to distant organs in organisms(Stratton, et al., 2009). 
All cancers can be viewed as an evolutionary process among the cell population within 
the microenvironment of a multicellular organism. Acquisition of deleterious genetic 
alterations confer a cell the ability to proliferate more effectively and renders it 
selectively advantageous(Stratton, et al., 2009). 
Functionally, cancer is characterized by sustained proliferative signaling, 
mechanisms to evade growth suppressors, and resistance to apoptosis. These factors 
enable replicative immortality through angiogenesis and activating invasion and 
metastasis(Hanahan and Weinberg, 2011). The underlying genetic instability, which 
causes such functional changes, encompasses several classes of DNA sequence changes. 
Typically these alterations are (i) single or multiple base substitutions, insertions and 
deletions; (ii) alterations in chromosome number which involves chromosomal gains and 
losses; (iii) chromosomal structural rearrangements (translocations, inversions, deletions) 
that give rise to gene fusions; (iv) over and under expression of genes(Haber and 
Settleman, 2007; Huber-Keener, et al., 2012; Lengauer, et al., 1998). 
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Though genetic instability is common in all cancer, not all instability drives the 
cancer. Many of the mutations in cancer could be non-deleterious or perhaps transiently 
required for tumor development. Only a small number of the vast number of mutations 
that occur in the genome drive deleterious neoplasms and even fewer are clinically 
actionable. For example, mutations in the protein kinase genes such as BCR and ABL 
have been remarkable targets for cancer treatment(Greenman, et al., 2007) and could be 
some of the key driver mutations. Moreover, many somatic mutations may not be 
deleterious until sufficient numbers of them have accumulated.  
 
1.3. Multiple Myeloma as Cancer type: 
Multiple Myeloma (MM) is clinically defined as a Plasma Cell (PC) neoplasm 
which result in clinical complications(Bataille and Harousseau, 1997). Myeloma 
progresses from Monoclonal Gammopathy of Undetermined Significance (MGUS) which 
is a benign monoclonal plasma cell expansion that progresses at 0.5 to 3% per year 
depending on monoclonal immunoglobulin levels(Kyle, et al., 2003). In some instances 
Smoldering Multiple Myeloma (SMM) which is an intermediate stage between MGUS 
and MM is observed though no clear genetic differences exist between SMM, MGUS  
and MM(Fonseca, et al., 2004). Like all cancers, myeloma is characterized by numerous 
genetic aberrations and the most commonly found events are given below: 
Aneuploidy: MM is characterized by frequent occurrences of aneuploidy(Debes-Marun, 
et al., 2003; Dewald, et al., 1985; Drach, et al., 1995; Fonseca, et al., 2004) with trisomies 
of 3,5,7,9,11,15,19 and 21 chromosomes and monosomies of 13,14,16 and 22 being the 
most common and these occurrences are independent of the stage (i.e. MGUS, SMM and 
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MM). Though the cut-off values for number of chromosomes have varied, aneuploidy 
segregates MM into four subcategories; hypo-diploid (<45 chromosomes), pseudo-
diploid (44-47 chromosomes), hyperdiploid (48-75 chromosomes) and tetra-ploid (>75 
chromosomes). The hyperdiploid variety usually has a comparatively lower number of 
structural chromosomal abnormalities. 
Translocations: Tetraploid, pseudodiploid and hypodiploid MM, generally referred to as 
non-hyperdiplod, have a high prevalence of IgH translocations t(4;14), t(11;14) and 
t(14;16). These translocations could be primary or secondary, i.e. those which are 
progression events. In general, all translocations barring the t(11;14) have been 
associated with poor prognosis. These translocations up-regulate various oncogenes, the 
most common ones being the Cyclin D class of genes. The consequence of the t(4;14) is 
the upregulation of WHSC1 and FGFR3 genes(Chesi, et al., 1997; Chesi, et al., 1998). 
WHSC1 has been known to deregulate H3 histone markers by affecting their 
dimethylation patterns(Marango, et al., 2008; Pei, et al., 2011). For the t(14;16) 
translocations, upregulation of MAF and MAFA genes are common.   
Deletions and amplifications: Tetraploid, pseudodiploid and hypodiploid MM, 
generally referred to as non-hyperdiplod, have a high prevalence of chromosome 13 
monosomy as well(Fonseca, et al., 2004). Karyotype data suggests interstitial deletions 
predominately involving band 13q14 are most common. However, some studies also 
found a rare bi-allelic inactivation in this region. Chromosome 1p deletions and 1q 
amplifications have also been associated with poor prognosis and a prognostic index has 
been developed based on these chromosome 1 aberrations(Shaughnessy, et al., 2007). 
The deletion which is the most significant in terms of correlation to disease related death 
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is the 17p13 involving TP53(Fonseca, et al., 2004). TP53 mutations are also associated 
with breast cancer, bladder cancer and adrenocortical carcinoma among others. 
Mutations: Recent exome sequencing studies have reported frequent mutations in 
KRAS, DIS3, NRAS, DNAH5, DIS3, TP53, CCND1 and FAM46C(Chapman, et al., 
2011; Lohr, et al., 2014; Walker, et al., 2012). Interestingly, FAM46C and DIS3 
mutations uniquely occur in multiple myeloma at a high frequency but not in other 
cancers(Chapman, et al., 2011; Lohr, et al., 2014). DIS3 mutations also occurred at a high 
rate in hyperdiploid patients (Lohr, et al., 2014). Exome sequencing studies revealed 
numerous oncogene activating mutations occurring in the same sample, which initially 
seemed redundant for a selective advantage. A closer look revealed up to 7 clonal 
populations within the same sample, suggesting that different oncogenic mutations drive 
different clones within the same sample(Lohr, et al., 2014). 
Gene expressions patterns in Myeloma: Gene expression profiling of MM, MGUS and 
normal plasma cells identified clear signatures in Myeloma(Zhan, et al., 2002). Gene 
expression profiling also enabled identification of subtypes in myeloma. Importantly, 
these gene expression studies have paved a way to identify highly aggressive tumors 
involving the t(4;14) and t(14;16) translocations through their unique gene expression 
patterns(Bergsagel and Kuehl, 2005; Broyl, et al., 2010; Zhan, et al., 2006). Gene 
expression array profiling of patient samples also led to the development of prognostic 
indices in myeloma capable of differentiating high-risk and low risk groups(Decaux, et 
al., 2008; Shaughnessy, et al., 2007). These findings subsequently determined the way 
patients would be treated. 
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As elucidated, through the usage of various high throughput genomic assays, our 
understanding of myeloma has improved tremendously. More recent studies have in an 
integrative fashion investigated the interplay between genome-wide copy number 
changes and exome-wide mutational spectrum and have shown that clonal heterogeneity 
is a common event in myeloma(Lohr, et al., 2014).  
Most of these studies focused on using a single assay, such as exome 
sequencing(Chapman, et al., 2011), mRNA sequencing(Yellapantula, et al., 2013) or 
gene expression arrays(Bergsagel and Kuehl, 2005; Broyl, et al., 2010; Decaux, et al., 
2008; Shaughnessy, et al., 2007; Zhan, et al., 2002; Zhan, et al., 2006) to understand the 
underlying biology of myeloma genome wide. Across all cancers in general, various 
methodologies have been developed to better understand the etiology of malignant 
neoplasms through integrative analysis across a large cohort of samples. Computational 
tools such as Genome Music(Dees, et al., 2012) and Mutsig(Lawrence, et al., 2013) help 
identify mutational significance when a set of variants is given as input. Algorithms such 
as GISTIC(Mermel, et al., 2011) identify genome and cohort-wide focal amplifications 
and deletions in cancer. More recently, as sequencing costs have become cheaper and the 
possibility of using multiple genome-wide assays on the same samples across large 
cohorts of samples has become realistic. However, few groups have addressed the need 
for integrative analysis to better understand cancer. Methods such as ABSOLUTE(Carter, 
et al., 2012) integrate copy number aberrations and somatic mutations to identify tumor 
purity, subclonal heterogeneity and consequently, mutational burden on the tumors. 
D’Antonio et al. (D'Antonio and Ciccarelli, 2013) in their paper show ways to effectively 
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integrate gene expression and mutational data in cancer. Rhodes et al. (Rhodes and 
Chinnaiyan, 2005) in their seminal paper discuss integrative analytical approaches using 
methods such as meta-analysis and gene enrichment analysis to better understand the 
underlying biology.  
Parsons et al’s (Parsons, et al., 2008) attempt to identify driver genes through 
integrative analysis of mutations, copy number changes and gene expression data is 
significant.  In their manuscript, a list of significant genes is identified through integrative 
analysis of exome sequence and copy-number aberrations. Further differentially 
expressed genes using SAGE are included into the analysis through pathway analysis. 
This integrative approach led to characterization of novel ground breaking genetic 
characterization of alterations in Glioblastoma along with discovery of recurrent 
mutations in the IDH1 gene. 
As seen from the various methods outlined above, there has not been an attempt 
to integrate Exome Sequencing data, RNA-Seq and aCGH data in a coherent fashion, 
though integration of such data is critical to better understand molecular processes of 
complex diseases at a genetic level. Though Parsons et al. attempt to integrate exome 
sequencing, copy number aberrations and SAGE data through pathway analysis, such 
analyses have limitations: (i) In using pathway enrichment analysis such as Metacore 
gene GO or Ingenuity pathway analysis, a list of genes is provided to identify involved 
pathways. However, all genes given as input in such analysis have equal weight, which is 
biologically untrue and is a significant drawback. (ii) RNA-Seq data compared to SAGE 
data has the opportunity to detect gene rearrangements that play a crucial role in the 
development of cancer. Gene fusions can occurs between constitutively well expressed 
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genes and a proto-oncogene and can result in overexpression of the oncogene. One such 
example is the @IGH-MMSET fusion common in myeloma. Gene fusions can also occur 
between two genes, which result in a novel fusion protein causing cancer. A common 
example of such fusions is the Philadelphia chromosome present in about 95% of patients 
with Chronic Myelogenous Leukemia(Heisterkamp, et al., 1985). Given the importance 
and prevalence of gene rearrangements in cancer, RNA-Seq which, has the ability to 
detect gene fusions ,can also be used in an integrative fashion to better understand disease 
etiology. 
Hence, applying integrative analysis is critical to better understand the genetic 
aberrations that cause cancer. In this thesis, we attempt to facilitate end-to-end integrative 
analysis approaches using exome sequencing, whole genome sequencing, mRNA-Seq, 
aCGH and methylation array data. Integrative analysis involves: 
1) Curating a list of high quality genetic aberrations from available 
datasets: The pre-requisite for integrative analysis is to identify a list of 
high quality variants from each available assay. Before identifying the 
variants within a given dataset, it is imperative to ensure that the data 
being analyzed is actually from the individual of interest. To this end, a 
java-based novel sample integrity checking tool, called “snpSniffer” was 
developed and is described in Chapter 2. Further, an end-to-end mutational 
calling pipeline called NGSPE for identifying variants with very high 
concordance and validation rates from exome sequencing data was 
developed. NGSPE has the ability to identify annotated variants from raw 
paired end sequencing reads and is described in Chapter 3. 
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2) Integrating the high quality datasets through novel integrative 
approaches: Chapter 4 describes methods for identification of putative 
aberrations causing dexamethasone resistance by integrating exome 
sequencing, RNA-Sequencing, long-insert whole genome sequencing, 
aCGH and methylation array data. Lastly, chapter 5 describes a novel 
integrative methodology to identify putative oncogenes and tumor 
suppressors in Myeloma cell lines using exome sequencing, RNA-Seq and 
aCGH. Further, the differences in Myeloma cell lines and patient samples 
at a molecular level are elucidated. We also identified that KDM6A 
deletion is over represented in myeloma cell lines and identify down 
stream targets of such inactivating mechanism. Since cell lines are useful 
in vitro models to better understand and resolve clinical problems in 
myeloma, chapter 5 describes cell lines most representative of patient 
samples for common subtypes in myeloma. 
In summary, integrative analysis involves curating a list of high quality genetic 
aberrations, followed by integrating them depending on the question at hand. Before 
identifying a list of high-quality aberrations it is important to ensure no sample mixups 
have occurred. Sample mixups are common and some groups have reported an average of 
a 3% mixup rate across large-scale sequencing studies(Keats, et al., 2013; Westra, et al., 
2011). Erroneously paired samples would result in loss of power for identifying causal 
variants, but could also result in deriving false conclusions from studies. To enable 
sample concordance, various groups have reported using SNP arrays for the 
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corresponding sample being analyzed by exome sequencing. This has an additional 
overhead of sample preparation and cost and could also result in further errors during the 
process. Some tools such as Mixupmapper(Westra, et al., 2011) have been developed to 
address mixups in expression measurement data such as RNA-Seq, but do not work for 
DNA  sequencing data. snpSniffer, as the only publicly available tool today developed to 
identify mixups, is presented in chapter 2. snpSniffer is the first step executed in the 
analysis described in this thesis before identifying variants in individual datasets for 
integrative analysis.  
NGSPE, described in chapter 3, provides answers for the challenging task of 
variant calling from DNA Sequencing data utilizing Illumina sequencing. Though various 
tools were developed for this purpose, there is no clear consensus as to the analytical 
process, the thresholds and parameters to be used during the analytical processes of 
variant calling. In NGSPE, we not only provide the list of analytical processes to obtain 
high quality variants, but also implemented the processes in a user-friendly tool that can 
install the dependencies and databases required and analyze sequences from raw reads to 
annotated variants. By comparing the validation rates across orthogonal assays and 
replicate samples with varying parameters, we define optimal parameters for variant 
calling using NGSPE.  Throughout chapters 4 and 5, which describe integrative 
methodologies for high throughput genomic datasets, NGSPE is extensively utilized for 
identifying high quality variants from exome sequencing data.  
Previous studies have acknowledged the need for integrative analysis 
methodologies to better understand the molecular processes in cancer.  However, there 
are very few datasets available that probe the same samples using multiple assays. 
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Moreover, even fewer studies have attempted to integrate these results in a coherent 
fashion. Previous methods have focused on integrative analysis by looking for recurrent 
events across a large cohort of samples or integrating diverse datasets through pathway 
analysis. We leveraged several central tenets of biology in our integrative analysis. For 
example, outlier expression originates from high level DNA amplifications or 
juxtaposition with DNA elements that drive high gene expression.  Moreover, we assume 
oncogenes will likely harbor recurrent events while tumor suppressors will follow the 
Knudsons’ Two-Hit hypothesis. The integrative analysis approaches described in this 
thesis attempt to glean knowledge in myeloma, addressing some of drawbacks in 
previous methods described. 
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CHAPTER 2 
SNPSNIFFER: A SNP BASED SAMPLE INTEGRITY CHECKING TOOL FOR 
DATA FROM NEXT GENERATION SEQUENCERS 
 
Abstract 
The reduction of high-throughput sequencing costs is resulting in more individuals being 
sequenced using a multitude of assays. Though this increases our ability to identify 
various molecular defects, it also results in a greater potential for sample mix-ups during 
the multitude of steps from sample acquisition to sequencing analysis. We present a new 
tool, snpSniffer, to detect if any such mislabeling events have occurred in DNA or RNA 
based sequencing assays. Using this tool ensures results from studies employing high 
throughput sequencing of exomes, whole genomes and transcriptomes, or combinations 
of these, are not misinterpreted. snpSniffer is implemented in Java and is currently 
supported to run on Linux/Unix based platforms. It is available for download for all non-
commercial users at ‘https://snpsniffer.sourceforge.net’. 
 
2.1. Introduction 
Ever decreasing per base sequencing costs and the development of numerous types of 
assays is enabling researchers to look at the genome in ways that were never before 
possible. While the reduction in cost enables sequencing of more samples, it also 
facilitates studies that interrogate different aspects of the genetic processes in a cell at a 
higher granularity. It is now a viable prospect to generate, for example, whole genome 
mate-pair sequencing, exome sequencing, RNA sequencing, DNA methylation 
sequencing, histone and transcription factor ChIP sequencing datasets on an individuals 
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tumor and constitutional samples in a cancer study. This enables identification of copy 
number abnormalities, structural rearrangements, somatic point mutations and indels, 
differential gene and/or transcript expression levels and epigenetic differences. 
This deluge of data contributes to knowledge discovery only if the data correctly 
represents the individuals in question. Should sample mix-ups or mislabeling events 
occur and be undetected, it could result in false conclusions. Various checks at different 
points in the workflow, from sample procurement to final analysis, should be employed 
to validate the integrity of the data. The stages where errors could occur are numerous but 
most commonly occur during: 
(i) Sample procurement and labeling at the source. 
(ii) During accessioning at the research or sequencing center where de-identification 
requirements often result in different identification codes at two different centers and 
(iii) Human error while preparing or documenting nucleic acid isolations, sequencing 
libraries (particularly demultiplexing indexes/barcodes) or positions on the sequencer.  
Though some of these steps could be automated to reduce such errors, mix-ups are 
still prevalent (Koboldt, et al., 2010; Lynch, et al., 2012; Westra, et al., 2011). Previous 
studies have shown that mixups in large sequencing studies occur at an average of 3% 
across all samples(Bock, 2012; Keats, et al., 2013; Westra, et al., 2011). While human 
errors during library preparation are common across all sequencing studies, sample 
labeling and accessioning procedures are typical in large-scale patient cohorts involving 
multiple project sites. Conventionally, researchers check for sample mixups by utilizing 
SNP arrays for genotype concordance(Chapman, et al., 2011; Koboldt, et al., 2010). This 
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adds an additional assay overhead and can also be unfeasible when enough patient 
material is not available for additional assays.  Though some tools (Westra, et al., 2011) 
have been developed to identify mix-ups in gene-expression data, no one tool exists that 
can effectively identify mix-ups in DNA and RNA-Sequence data. 
Here we present snpSniffer, a genotype concordance based sample integrity checker. 
The objective of snpSniffer is to analyze two or more sets of mapped DNA or RNA 
sequencing reads in a bam format and determine if the sequences originate from the same 
individual. Implementing snpSniffer involved curating a new SNP panel that can used for 
exome and RNA-Seq data along with the development of a user friendly java based tool 
to identify sample mixups from aligned reads. Though devised for cancer datasets where 
the chances of sample mix-ups are higher due to tumor/normal comparative analysis, the 
tool can also be applied to similar datasets employing any combination of whole genome 
sequencing (WGS), exome sequencing or RNA-Seq. Using this tool as part of a standard 
protocol before any analysis on the data begins would reduce false positives and ensure 
biologically relevant results. 
 
2.1.1. Utility of SNPs for sample identification: In forensics, crime scene samples 
are matched with a suspects DNA using polymorphic Short Tandem Repeats (STRs) 
(Sanchez, et al., 2006). SNP panels were proposed to achieve the same utility (Butler, et 
al., 2007; Gill, 2001) with the added advantage of SNPs having lower mutation rates 
compared to STRs (Sanchez, et al., 2006). Previous studies have reported a 19 SNP panel 
(Kidd, et al., 2006) and a 40 SNP panel (Pakstis, et al., 2007) showing the utility of SNPs 
for individual identification. Sanchez et al. reported a 52 SNP panel (Sanchez, et al., 
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2006) with very high discriminatory power that is accepted for forensic investigations in 
many European countries. Later, a panel based on a 92 SNP list with discriminatory 
power comparable to the 13 STR CODIS panel was published (Fang, et al., 2009). These 
studies have established that SNPs can be used for individual identification and also have 
discriminatory power similar to that of the CODIS panel used for forensic investigations. 
Though these well-curated markers can be used in high throughput sequencing 
studies, most of these SNPs fall within intergenic and intronic regions that are not 
covered in exome and RNA sequencing studies that are prevalent today. To support the 
analysis of these types of data, which are focused on exons, we identified a SNP panel 
that is restricted to exons and can be used in conjunction with our snpSniffer tool. 
 
SNP selection criteria: To identify a SNP list that provides strong discriminatory power 
we selected SNPs that passed certain thresholds. Similar to previous studies we identified 
SNPs with:  
(i) High Minor Allele Frequency (MAF): Having a high minor allele frequency 
ensures a higher spread of probability of having each of the possible genotype in a 
population. For example, if ‘B’ is the minor allele for a SNP ‘AB’ in a population, 
then having higher frequency of ‘B’ allele ensures that the proportion of 
genotypes ‘BB’ and ‘AB’ is high. This gives higher discriminatory power as in a 
given population there is greater spread of ‘AA’, ‘AB’ and ‘BB’ genotypes. 
Sanchez et al reported a requirement of minimum 30% heterozygosity (0.28 
minor allele frequency) in at least one population and minimum 20% 
heterozygosity (0.17 minor allele frequency) in all populations for achieving the 
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discriminatory power for identifying individuals from a world population. Kidd et 
al used SNPs that have a heterozygosity value of grater than 0.4. 
(ii) SNPs that are not in Linkage Disequilibrium (LD): Two or more SNPs in 
perfect correlation with each other are not informative as a certain genotype in 
one position always corresponds to a particular genotype in an other. Hence, 
statistically independent SNPs with r2 or D’ values below a certain value should 
be used. While, Sanchez et al used only those SNPs, which are 100 Kb apart so 
that the SNPs are not in LD, Kidd et al used only those SNPs where this r2<0.25. 
(iii) The SNPs should have low variation in allele frequency in different races 
ie. low Fst: It is common to see that the allele frequencies vary across different 
populations. A SNP with a low MAF in a certain population is not informative as 
the allele is more frequent across all individuals in a population. Ideally, the MAF 
should be greater than the threshold we chose for all the populations and selecting 
markers based on a low fixation index (Fst) has the benefit of balancing selection 
bias in a particular population. The international Hapmap project concluded that 
the autosomal Fst score across three different populations to be 0.12. Kidd et al’s 
35 SNP panel had 19 SNPs whose Fst was below 0.06 and the remaining were 
above it. A higher threshold value would necessitate inclusion of more SNPs to 
achieve the same discriminatory power.  
 
 
  20 
(iv) The SNPs should be in Hardy-Weinberg equilibrium: We expect the SNPs 
to be in Hardy-Weinberg equilibrium as the Hapmap project from which the SNPs 
will be derived will be minimally influenced by the disturbing factors such as 
mutations, natural selection, nonrandom mating, genetic drift, and gene flow. 
Additionally, Haploview was used to check if the SNPs adhere to Hardy-
Weinberg equilibrium. 
Kidd et al. identified a 19 SNP panel which had MAF greater than 0.4 with 
corresponding LD (r2) <=25% for 99.5% of the SNPs along with Fst <0.06 with average 
match probability of 10-7 and discriminatory power of > 0.9999999 (Kidd, et al., 2006). 
Similarly, Sanchez et al identified a 52 SNP panel with MAF >= 0.28 and required that 
SNPs be greater than 100kb apart. They also required each of these SNPs to be present on 
every autosomal p and q arms (excluding chromosome 19), which resulted in a 
discriminatory power of at least 0. 999999 (Sanchez, et al., 2006) and mean match 
probability of at most 5 x 10-19. 
 
2.2. Methods 
Developing the SNP panel involved curating a list of SNPs for genotype concordance 
and developing a tool to enable genotype concordance from exome/whole genome or 
RNA Sequencing data. These steps are described below: 
2.2.1. SNP panel selection: All reported genotypes and phased linkage disequilibrium 
files in the Caucasian (CEU), Chinese (CHB), Japanese (JPT) and Yoruban (YRI) 
populations from the International HapMap Project (Thorisson, et al., 2005) (Hapmap 3 
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draft release #2, http://hapmap.ncbi.nlm.nih.gov/downloads/ld_data/2009-
02_phaseIII_r2/00README.txt) were downloaded. These populations were chosen since 
these races are extensively characterized in major sequencing studies such as the 1000 
Genomes project (Siva, 2008) and NHLBI Exome sequencing project (Server, 2013; 
Server and NHLBI, 2012). These extensive projects have identified a large number of 
SNPs with a high minor allele frequency (Table 1). Moreover, these populations have a 
sufficient number of genotypes that pass the various filtering criteria and would achieve 
adequate discriminatory power.	  
S. No Race No. of positions with MAF >0.40 
1 ASW 260629 
2 CEU 494038 
3 CHB 467179 
4 CHD 241953 
5 GIH 269343 
6 JPT 459324 
7 LWK 250204 
8 MEX 256788 
9 MKK 258631 
10 TSI 266103 
11 YRI 474671 
Table 1:Shows number of positions having minor allele frequency greater than 0.4 by 
race. 
 
From the selected populations, MAF was calculated and only those SNPs with MAF 
> 0.4 across all 4 selected Hapmap populations were retained for further analysis. This 
left a total of 26572 SNPs. Since we want the tool to work with whole exome and RNA 
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sequencing studies, SNPs present in CDS regions defined by refSeq or Gencode that are 
also targeted by Agilent SureSelect V4 + UTR and TruSeq exome capture kits (Giuffre, 
et al., 2011) were retained. Further filtering was done for those SNPs where pairwise LD 
(r2) is never above 0.2. These thresholds for MAF and LD are conservative based on 
published forensic panels previously described (Kidd, et al., 2006; Sanchez, et al., 2006). 
Since we also intend the tool to work with RNA-Seq data for all tissue types, no 
filtering of SNPs based on gene expression levels was done. Instead, genotypes for each 
run are dynamically selected, including all genotypes calculated to be high quality 
(QUAL>50). We also ensured that no meaningful deviations from Hardy-Weinberg 
equilibrium occurred in these SNPs. A final list of 437 SNPs passed the criteria 
mentioned above and were used for sample concordance (Appendix A). The match 
probability for each loci was calculated on the Hapmap population by obtaining the sum 
of the squared frequency for each of the possible genotypes. Assuming independence, 
match probabilities for 152 loci with highest values were multiplied to obtain an overall 
match probability of 5.23915e-63. In general, comparison between two RNA-Seq 
samples has the least number of available genotypes for matching for sample 
concordance (Fig. 5). Hence, we used 152 loci since it’s the rounded mean value of 
available genotypes for matching between any 2 RNA-Seq samples in our test datasets.	  
2.2.2. Implementation and Usage: There are three steps associated with running the 
snpSniffer. 
2.2.2.1. Generate the genotypes in a vcf format at specific genomic loci: To 
enable comparison of genotypes at the curated loci, genotypes at the curated 
positions should be generated in a vcf 4.1 format. This is possible through 
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snpSniffer which uses Samtools (Li, et al., 2009) as its engine. This step can be 
run in parallel. 
2.2.2.2. Adding the genotypes generated to a flat file: The generated genotypes 
along with all other genotypes from samples in a specific study will be saved in a 
flat file (Table 2). Only genotypes that pass a QUAL>=50 threshold will be 
added. Genotypes at other positions where genotypic information has low quality 
scores or is unavailable will be marked as ‘NN’. 
 
Sample Sample1 Sample2 …. SampleN 
Chr1:Position1 AA BB … … 
Chr2:Position2 AB AA … … 
Chr3:Position3 AA AB … … 
… … … … … 
Table 2: Shows the structure of the database where genotypes will be stored. For N 
samples there would be a total of N+1 columns and 438 rows. The first column has the 
chromosome and position separated by ‘:’ followed by genotypes of these positions for 
each sample.  Rows represent each of the positions and the corresponding genotype for 
each sample. 
 
2.2.2.3. Sample concordance check: The genotypes generated are compared, pair-wise, 
for samples of interest. The total number of genotypes available for each pair-wise 
comparison, the matching number of genotypes and the ratio of the matches to the total 
number of genotypes available for comparison are given as output. To obtain the 
appropriate thresholds for identifying matched and unmatched samples, we used an 
internally available cell line dataset as our training set. We separated the samples based 
on the bimodal distributions of the ratio values (Figure 1). These distributions varied 
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from 0.84 to 1 for the upper distribution. For the lower distribution, the ratio values 
ranged from 0.28 to 0.6. To obtain the thresholds to identify true matches and true non-
matches, we set the threshold by identifying the midpoint of the obtained thresholds from 
cell line cohort ie. Midpoint of 0.6 and 0.84.  This resulted in a threshold value of 0.72 
for identifying any mismatches. Hence, ratio >0.72 signifies a match whereas a ratio 
<0.72 signifies a mismatch. 
2.2.2.4. Identify expected matches: Using snpSniffer, all expected matches can be 
identified by passing as input the database of genotypes of all samples, the delimiter to 
define the sample name and the number of delimiters to define the sample name. Pairwise 
comparisons for each sample across all other samples can be done in a single step. The 
output for this step would be a list of all matched samples as per the user-given criteria 
that have a ratio value of above 0.72. For the convenience of the users, results of all 
pairwise comparisons, including sample name, number of SNPs available for 
comparison, the number of matched SNPs and the ratio for each pairwise comparison is 
given as output in a text file. 
2.2.2.5.Identify not-expected matches: All not-expected matches can be identified in a 
single step using snpSniffer giving as input the database of genotypes, the delimiter to 
define a sample name and the number of delimiters to define the sample name. The 
output for this step would be the list of all matched samples that have a ratio value below 
0.72 and the list of all samples involved in a pairwise comparison that have a ratio value 
above 0.72. The results of all pairwise comparisons are also provided in a text file. 
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Figure 1: Histogram (a) and jitter plots (b) of the matches to total comparisons ratio in 
the cell lines show a clear demarcation between mismatch and match events. This is 
indicated by blank space between 0.60 and 0.84 in the plots, showing that the SNP panel 
has adequate discriminatory power. 
 
2.2.3. Data and Pre-processing: All mRNA and exome sequence reads from our 
collection of myeloma cell lines procured from ATCC, DSMZ, ECACC, JCRB and other 
non-commercial sources were used for testing snpSniffer. These cell lines were used as 
they were tested for their authenticity using an orthogonal approach utilizing 
qPCR(Keats, et al., 2007).  
An additional 29 samples from the Multiple Myeloma Research Foundation (MMRF) 
CoMMpass study having matched tumor/normal exomes with corresponding tumor 
RNA-Seq were also used. These assays were sequenced using Illumina HiSeq 2000 
instruments with read lengths of 83x83 bp or 101x101 bp. Exomes achieved a median 
coverage across all samples of 84.3x (Fig. 2) while RNA-Seq samples achieved a median 
of 151.1 million paired-end reads per sample (Fig. 3). 
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Figure 2:Shows mean coverage across exome for human multiple myeloma cell lines and 
MMRF patient samples 
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Figure 3: Shows number of reads in million for all HMCL and MMRF patient RNA-Seq 
samples 
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mRNA reads were aligned using Tophat 2.0.4 (Trapnell, et al., 2009) with appropriate 
settings optimized to the read length. Exomes sequencing runs were aligned using BWA 
(Li and Durbin, 2010) followed by a pipeline defined by the GATK best practices 
(McKenna, et al., 2010). snpSniffer was run to generate genotypes, add genotypes to the 
database, generate concordance ratios and make pairwise comparison between each 
sample and the remaining samples in the database. 
To further test the utility of the tool and to determine if closely related individuals are 
identified as separate individuals, we screened the related samples in the 1000 genomes 
project dataset. We ran the snpSniffer on related individuals testing family trios and 
siblings by obtaining mapped reads of samples which pass the following criteria. For 
testing purposes, we selected related samples that were sequenced on Illumina/Solexa 
instruments, were categorized as high coverage and belong to one of our populations of 
interest, namely Yoruban, Caucasian, Chinese and Japanese. To test if we could separate 
parents from their children and each other we checked the concordance within the CEU 
population trio NA12878, NA12891, NA12892 and the YRI trio NA19240, NA19239, 
NA19238. To test if we could separate siblings, CHS samples HG00501 and HG00524 
along with TSI samples NA20526 and NA20792 were included for testing.  
2.3. Results 
 The results of pair-wise comparisons between MMRF samples with ratio >0.72 
(potential matches) were examined. Two mix-up events in the samples from the MMRF 
study were identified (Figure 4). Numerous mismatches in the cell line samples were also 
observed. Incidentally, these mismatches in cell lines were all known sub lines from the 
same contributing individual suggesting that the SNPs used for comparison have 
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discriminatory power to detect samples that have gone through multiple passages and/or 
are sub-clonal populations (Appendix B). Additionally all samples with ratios < 0.72 
(potential mismatches) were examined for any potential expected matches that did not 
share the same genotypes. None were found. As expected, comparison of samples 
between RNA/RNA pairs or RNA/exome pairs utilize a reduced number of SNPs 
compared to comparisons between exome/exome data (Fig. 5 & 6). This is due to 
expression of only a subset of the coding sequence in a give tissue type.  
 
Figure 4:Shows genotype concordance ratios for expected and not-expected pairs 
in the MMRF study. Two sample mix-ups, M1135 and M1184 between tumor (T) 
DNA/RNA and normal (N) DNA are shown. 
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Figure 5: Shows the number of genotypes called with high confidence and available for 
concordance check in each potential assay type pair in pairs with concordance ratios 
below 0.66.  The number of genotypes available for RNA/RNA and RNA/Exome 
comparisons is reduced because only a fraction of individual genes in the genome are 
expressed in any given tissue type and genotypes can only be determined for genes with 
sufficient coverage, which is dependent on the expression level of the individual gene.  
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Figure 6: Shows the number of genotypes called with high confidence and available for 
concordance check in each potential assay pair in pairs with concordance ratios above 
0.79. The number of genotypes available for RNA/RNA and RNA/Exome comparisons is 
reduced because only a fraction of individual genes in the genome are expressed in any 
given tissue type and genotypes can only be determined for genes with sufficient 
coverage, which is dependent on the expression level of the individual gene. 
 
 
 
 
  32 
For the 1000 genomes dataset including 10 individuals involving related 
individuals, no concordance was found based on our established cut off (Table 3; Figure 
7). snpSniffer had the discriminatory power to even discern children and siblings who are 
genetically very similar.  
 
1000 genomes Sample 1 1000 genomes Sample 2 Ratio 
NA12878 NA12891 0.51 
NA12878 NA12892 0.54 
NA12891 NA12892 0.44 
NA19240 NA19239 0.57 
NA19240 NA19238 0.56 
NA19239 NA19238 0.41 
HG00501 HG00524 0.64 
NA20526 NA20526 0.62 
Table 3: Shows the 1000 genomes trios/siblings and concordance ratios within each. 
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Figure 7: Shows concordance ratios for related individuals from the 1000 genomes 
dataset. “SIBLINGS” column shows ratio values between 2 sibling pairs. “FAMILY-
TRIO” column shows ratio values within related individuals in a family. “ALL-OTHER” 
column shows ratio values between all unrelated individuals within this subset.  
 
2.4.Conclusion and Discussion 
The rise of high throughput sequencing technologies is changing how we conduct 
research, while opening new avenues to understand the genetic basis of many diseases. 
For example, the MMRF CoMMpass study involves the analysis of 1000 patients who 
are followed clinically for a minimum of 5 years. In this study patient tumor-normal 
samples are sequenced using WES, RNA-Seq and mate-pair WGS sequencing at 
diagnosis and relapse. Ensuring that each result file represents the same individual is 
critical; otherwise the primary goal of identifying prognostic and therapeutic models 
could be hindered. While several groups have been utilizing SNP arrays for genotype 
concordance in a research setting, running additional assays may not be possible when 
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there is limited amount of tissue available. Genotype concordance using SNP arrays also 
does not address the problem of sample mixups that occur during library preparation. 
These drawbacks of SNP arrays are addressed through snpSniffer. 
Moreover, next generation sequencing has come of age and is rapidly being used as a 
clinical assay. Though CLIA certified laboratories have rigorous quality control 
procedures in place to minimize mix-ups, human error is inevitable. Including snpSniffer 
in such pipelines would add another checkpoint to ensure sample integrity. It is important 
that sample concordance checks are a part of any standard analysis pipelines using NGS 
to ensure biologically relevant results. To this end, snpSniffer as the only tool available 
till date will make implementation of such pipelines easier. 
Although snpSniffer is designed for exome, whole genome and RNA Sequencing 
datasets, it can also be used to identify mixups in sequencing data of a small panel of 
genes, which is common practice in cancer today. SNP array data can also be used in 
conjunction with snpSniffer to identify mixups. The prerequisite for identifying mixups 
in a small panel of genes or SNP Arrays is that a sufficient number of curated SNPs 
should have genotype data available for comparison. 
We show snpSniffer is able to discriminate cell lines that have gone through multiple 
passages and/or are subclonal populations by using myeloma cell lines from commercial 
and non-commercial sources. We tested all family trios and siblings in the 4 selected 
Hapmap populations, having Illumina/Solexa datasets in the 1000 Genomes Project and 
show that snpSniffer has the discriminatory power to identify related individuals in 
family trios and siblings. 
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Through our ongoing projects, such as the MMRF CoMMpass project, we show the 
utility of snpSniffer by detecting 2 patient mixups in a cohort of 32 samples. In general, 
samples mixups occur at an average of 3% in large scale sequencing studies involving 
multiple sites(Bock, 2012; Keats, et al., 2013; Westra, et al., 2011). A 3% mixup rate is 
significant and if undetected, can alter current interpretations and treatment regimens in a 
disease of interest. For example, the CD1 class in Myeloma is defined by over-expression 
of Cyclin-D1 along with a t(11;14) rearrangement and is harbored by 5% of Myeloma 
patients(Broyl, et al., 2010). Sample mixups of one of the assays in the CD1 class alone, 
across a large cohort of samples, would completely change the interpretation of the 
biology of this particular class. 
 Utilizing snpSniffer before integrative analysis is critical as such mixups 
occurring only within a single assay can have grave consequences when the data is 
integrated. For example, consider a case where BRAF mutations in a certain sample S1 
are detected by exome sequencing. @IGH-MMSET fusion is also identified using RNA-
Seq in another sample S2 mislabeled as S1.  In a chance event that two such mixups 
occur in a 100 sample cohort, it would lead to false conclusions that 2% of samples that 
have BRAF mutations also harbor @IGH-MMSET fusions which could have significant 
therapeutic implications. 
 We conclude that while a great deal of quality control procedures are followed in 
sequencing studies(Chapman, et al., 2011; Koboldt, et al., 2010), preventing accidental 
mislabeling events is not easy. These mislabeling events could have far reaching 
consequences and identifying such events is very important. snpSniffer enables 
identifying such mislabeling events. 
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CHAPTER 3 
NGSPE: A PIPELINE FOR END-TO-END ANALYSIS OF DNA SEQUENCING 
DATA AND COMPARISON BETWEEN DIFFERENT PLATFORMS 
 
Abstract 
We present NGSPE, a pipeline for variation discovery and genotyping of pair-
ended Illumina next generation sequencing data (http://ngspeanalysis.sourceforge.net/). 
This pipeline not only describes a set of sequential analytical steps, such as short reads 
alignment, genotype calling and functional variation annotation that can be conducted 
using open-source software tools, but also provides users a set of scripts to install the 
dependent software and resources and implement the pipeline on their data. A sample 
summary report including the concordance rate between data generated by this pipeline 
and different resources as well as the comparison between replication samples of two 
commercial platforms from Illumina and Complete Genomics is also provided. 
Furthermore, some of the mutations identified by the pipeline were verified using Sanger 
sequencing.  
 
3.1. Introduction 
Recent advances in next-generation sequencing (NGS) technologies provide 
relatively inexpensive, reliable high throughput DNA sequence information, making it 
possible to search through entire genomes for variants that influence genetic traits in 
population studies(Choi, et al., 2009; Lupski, et al., 2010; Ng, et al., 2010). The 
application of NGS technologies, through whole-genome, whole-exome and whole-
transcriptome approaches, has resulted in substantial advances in genetic studies for 
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common human diseases (Consortium, 2010; Yi, et al., 2010). Although a variety of 
analytical tools have been developed to process short reads of DNA sequence generated 
by diverse sequencing machines(DePristo, et al., 2011; Li and Durbin, 2009; McKenna, 
et al., 2010; Quinlan and Hall, 2010; Wang, et al., 2010), performing an end-to-end 
analysis, from raw reads to a list of high quality annotated variants, of next generation 
genomic sequence data remains a challenging task. Questions may arise as to what steps 
are involved in the analytical process; what are the software tools that can perform each 
analytical step; what are the parameters to be utilized with these tools; and what 
computing resources are required. In this manuscript, we describe NGSPE, an open-
source software pipeline and the associated tools capable of discovering high-quality 
genomic variation in DNA sequence data. A comparison is drawn between results 
generated by this pipeline and those generated using other NGS analysis tools and also 
compared the variants identified by Illumina and Complete Genomics on the same 
genomic sample. Subsequently, we validated a randomly chosen subset of the variants 
identified by NGSPE at various quality thresholds using Sanger sequencing 
 
3.2 Methods and materials 
Whole-genome sequence (WGS) data were initially generated on 2 human blood 
samples 01 and 05. 01 was sequenced by BGI, Shenzhen, China (01_WGS_ILLUMINA), 
while sample 05 was sequence by both Illumina, Inc (San Diego, CA) 
(05_WGS_ILLUMINA) and Complete Genomics (Mountain View, CA) 
(05_WGS_COMPLETE) at a mean coverage of ~40×. Additionally, whole-exome 
sequence (WES) libraries were prepared on 4 human blood samples, where the exons 
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were captured using the Agilent SureSelect V1 Human all exon 38MB kit (Agilent 
Technologies, Santa Clara, California, USA). These were subsequently resequenced by 
Shangai Bio Corporation (North Brunswick, New Jersey, USA) using the Illumina GA 
IIx platform. These 4 WES samples included the same individual (01) who had 
undergone WGS described above and three additional subjects who were sequenced 
twice as blind replicates (02, 02_dup, 03, 03_dup, 04, 04_dup). The samples sequenced 
and the platform used on each of these is shown in Table 1. 
 
Sample Complete Genomics WGS Illumina WGS Illumina WES 
01 -- ✓ ✓ 
02 -- -- ✓ 
03 -- -- ✓ 
04 -- -- ✓ 
02_dup -- -- ✓ 
03_dup -- -- ✓ 
04_dup -- -- ✓ 
 05 ✓ ✓ -- 
Table 1 Shows the different samples compared and which sequencing method was used 
on each of these. 
 
The analysis pipeline consisting of 27 steps was established for DNA sequence 
analysis.  The steps are illustrated in Figure 1 and detailed in Appendix C. Briefly, the 
analysis process involves alignment to reference genome of fastq-formatted paired-end 
data, generation of sam and bam files, duplication removal, table recalibration, indel 
  39 
realignment, variant identification, variant annotation and variant quality score 
recalibration. The default values for parameters were used wherever appropriate. To 
complete the various steps, the pipeline uses a series of open source programs: 
i. BWA (http://sourceforge.net/projects/bio-bwa/files/) 
ii. BEDTools 
(http://code.google.com/p/bedtools/downloads/detail?name=BEDTools.v2
.12.0.tar.gz) 
iii. GATK 
(ftp://ftp.broadinstitute.org/pub/gsa/GenomeAnalysisTK/GenomeAnalysis
TK-latest.tar.bz2) 
iv. Picard (http://sourceforge.net/projects/picard/files/) 
v. ANNOVAR (http://www.openbioinformatics.org/annovar/) 
vi. snpEff (http://snpeff.sourceforge.net) 
The following software versions were used for the analysis: BWA 0.5.9, BEDTools 
2.12.0, GATK 1.6, Picard 1.4.3 and snpEff 2.0.5. NCBI build 37 was used as reference 
for alignment. These versions of software and resources can be downloaded and installed 
using the installation script (install.sh) provided. However, some software, such as the 
GATK and ANNOVAR, require users to agree to terms and conditions of the software 
before they can download them. Hence, these programs were excluded from the software 
installation script and will have to be installed by the user.  If new or improved tools 
become available to execute certain analytical steps, users can easily replace them in the 
workflow process. The pipeline can be run on a stand-alone Linux workstation or in a 
High Performance Computing (HPC) environment. Executable scripts for both 
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environments are available for download at 
http://sourceforge.net/projects/ngspeanalysis/files/Shell_Scripts/. A number of publicly 
available genomic and biological datasets are used at various stages of the pipeline and 
these can be downloaded from http://ngspeanalysis.sourceforge.net/documentation.html.  
The analysis process was carried out on both a computer workstation with Red Hat 
Enterprise Linux (release 6.0) operating system (CPU:  Intel Xeon W3550 3.06 
8MB/1066 QC; Memory: 16GB) and the Saguaro High Performance Computing cluster 
computer at Arizona State University (http://a2c2.asu.edu/resources/saguaro/). For each 
exome or genome analyzed, 8 processor nodes were used (8X Intel Xeon E53XX 1.8-3.0 
8MB/1066 QC; Memory: 8X 2GB).  Comparison of the concordance rate was done using 
the statistical analysis system of the SAS Institute (Cary, North Carolina, USA). Data 
used for comparison between Illumina and Complete Genomics whole genome 
sequencing platform was filtered as suggested (Quality value should be greater than 20 in 
Illumina and pass VQHIGH in Complete Genomics, respectively). 
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Figure 1:The pipeline for variation discovery and genotyping from next-generation DNA 
sequencing (Appendix B). (# Step 17, coverage calculation could be done by either 
GATK or BEDTools) 
 
3.3.  Results 
Each exome data set contained ~4.5 billion bases of raw sequence data, or about 10 Gb of 
disk space.  For each exome, steps 2 to 21 were completed in ~15 hours (not including 
the coverage calculation step) using a single computer workstation.  In comparison, 
samples could be run in parallel using the Saguaro HPC environment, allowing 
completion of all 7 samples in less than 20 hours. The per-base coverage of these samples 
was determined to be approximately ~42X. The total covered exon bases are ~38M, 
which is consistent with the Agilent kit’s capture size. As a note, DNA sequences 
captured with the Agilent kit were not all exomic; a sizeable portion of non-exome 
sequence (~350M) was also extracted. A total of 221,209 high quality score SNPs 
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(quality value >=50) were obtained by combining all variants detected in the 7 WES 
experiments (Tables 2, 3). Of these SNPs, 30,905 mapped within an exon, while 190,304 
mapped outside of predicted exons. There were 150,793 transitions and 70,416 
transversions, giving a Ti/Tv ratio of 2.14, which is consistent with the expected ~2-2.1:1 
ratio observed in the 1000 genomes data (Consortium, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 Summary of Genomic Variant Analysis 
 
Base A C G T 
A 0 9,326 36,969 6,087 
C 8,766 0 10,998 38,594 
G 38,643 10,953 0 8,696 
T 6,187 36,587 9,403 0 
Table 3 Summary of base changes (Rows are reference bases, columns are changed 
bases). 
 
For the sample 01 that underwent both whole genome and whole exome 
sequencing, the variant call concordance was compared between the SNPs identified with 
our pipeline (on the exome data) and the SNPs identified with SOAPsnp 
(http://soap.genomics.org.cn/soapsnp.html) by BGI. A SNP was considered concordant 
Total SNPs 221,209 
Exonic SNPs 30,905 
Non-exonic SNPs 190,304 
Transitions 150,793 
Transversions 70,416 
Ti/Tv ratio 2.1415 
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when the chromosome, position, the reference allele and the alternate allele in the 
samples being compared match. The concordance rate (CR) increased greatly, from 
73.6% to 99.5%, when SNPs with low quality scores were excluded (Table 4). 
 
WGS  
Quality 
WES  
Quality 
SNPs with  
same genotype 
Total SNPs 
Concordance  
rates 
all_snp_included 152,972 207,811 73.61% 
>50 >50 96,304 98,595 97.68% 
>50 >80 86,219 87,527 98.51% 
>80 >50 82,374 84,495 97.49% 
>80 >80 73,892 75,070 98.43% 
>80 >100 68,700 69,434 98.94% 
>90 >100 57,953 58,644 98.82% 
>90 >200 43,743 43,939 99.55% 
Table 4 SNP calling concordance rate report from WGS result and WES result of sample 
01. 
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Quality value 
threshold 
Sample Replicate SNPs with 
same genotype 
Total 
SNPs 
Concordance 
rate 
Include SNPs 
with low 
quality in both 
02 02_dup 52,640 58,200  
03 03_dup 52,725 58,200  
04 04_dup 52,889 58,200  
  158,254 174,600 90.64% 
Exclude SNPs 
with low 
quality in both 
02 02_dup 36,262 38,900  
03 03_dup 36,315 38,900  
04 04_dup 36,489 38,900  
   109,066 116,700 93.46% 
Missing SNPs 
deleted 
02 02_dup 36,063 38,170  
03 03_dup 35,913 38,171  
04 04_dup 36,250 37,969  
   108,226 114,310 94.68% 
>30 
02 02_dup 8,513 8,639  
03 03_dup 8,458 8,704  
04 04_dup 8,553 8,599  
   25,524 25,942 98.39% 
>50 
02 02_dup 8,099 8,213  
03 03_dup 8,159 8,319  
04 04_dup 8,195 8,260  
   24,453 24,792 98.63% 
>100 
02 02_dup 7,490 7,571  
03 03_dup 7,426 7,576  
04 04_dup 7,480 7,513  
   22,396 22,660 98.83% 
>200 
02 02_dup 6,463 6,507  
03 03_dup 6,448 6,548  
 04 04_dup 6,483 6,505  
   19,394 19,560 99.15% 
Table 5: SNP calling concordance rate report on three duplicate pairs. 
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We also compared CRs for the 3 WES duplicates using different quality value 
thresholds (Table 5). The CR increased from 90.64% to 94.68% when SNPs identified in 
only one of the two replicates were excluded. Further increasing the quality value 
thresholds raised CRs to 98-99% (Table 5). Similar trends were observed for INDELs, 
where the CR increased from 91.40% to 97.16% when increasing the quality score 
thresholds (Table 6). 
As for the comparison of two major commercial whole genome sequencing 
platforms from Illumina and Complete Genomics applied to the same human blood 
sample 05, our result indicates a close concordance. Illumina reported 3,571,370 SNPs 
and 650,369 INDELs with quality value >=20 while Complete Genomics identified 
3,194,753 SNPs and 375,475 INDELs passed their VQHIGH filter as defined by 
Complete Genomics. There were 3,037,640 SNPs and 320,058 INDELs which were 
called by both platforms (Figure 2). (Additionally, Complete Genomics reported ~72k 
substitutions which were a series of nearby reference bases had been replaced with a 
different series of bases in an allele, while Illumina did not report these variants.) When 
comparing the genotypes of these overlapping variants, the vast majority, 3,033,769 
SNPs and 315,871 INDELs, were in genotype consistence. The concordance rate is 
approximately 99.87% and 98.69% for SNPs and INDELs, respectively. As for the 
distinct variants detected in each platform, Illumina reported more variants than 
Complete Genomics. We then compared the distribution of the variants for the two 
platforms (Table 7). We found that there is no significant difference between the two 
platforms on the distinct variants’ location except for the 5’ UTR (Table 7). 
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Quality value 
threshold 
Sample Replicate 
INDELs with 
same genotype 
Total 
INDELs 
Concordanc
e rate 
All INDELs 
included 
02 02_dup 2,414 2,619  
03 03_dup 2,364 2,619  
04 04_dup 2,403 2,619  
   7,181 7,857 91.40% 
>30 
02 02_dup 280 293  
03 03_dup 274 284  
04 04_dup 266 281  
   820 858 95.57% 
>50 
02 02_dup 263 273  
03 03_dup 262 270  
04 04_dup 253 266  
   778 809 96.17% 
>100 
02 02_dup 239 248  
03 03_dup 233 240  
04 04_dup 235 242  
   707 730 96.85% 
>200 
02 02_dup 213 220  
03 03_dup 198 204  
04 04_dup 205 210  
   616 634 97.16% 
Table 6: INDEL calling concordance rate report on three duplicate pairs. 
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Variant 
Exon & 
splicing 
(%) 
5' UTR 
(%) 
3' UTR 
(%) 
ncRNA 
(%) 
Intron 
(%) 
Intergenic 
(%) 
Total 
(%) 
Illumina 
SNP 
3,042 
(0.69) 
1,328 
(0.30) 
1,888 
(0.43) 
17,922 
(4.04) 
116,208 
(26.23) 
302,605 
(68.31) 
442,993 
(100) 
Complete 
Genomics 
SNP 
476 
(0.61) 
65 
(0.08) 
302 
(0.39) 
3,124 
(4.00) 
21,138 
(27.03) 
53,086 
(67.89) 
78,191 
(100) 
Illumina 
INDEL 
316 
(0.10) 
416 
(0.14) 
2,022 
(0.65) 
8,747 
(2.81) 
108,666 
(34.91) 
191,085 
(61.39) 
311,252 
(100) 
Complete 
Genomics 
INDEL 
42 
(0.10) 
25 
(0.06) 
327 
(0.76) 
1,074 
(2.48) 
16,901 
(39.09) 
24,864 
(57.51) 
43,233 
(100) 
Table 7 Distribution of the distinct variants detected by Illumina and Complete 
Genomics for sample 05. 
 
These differences in the 5’ UTR region variants we believe is due to the poor 
alignment in this highly repetitive region. The standard library fragment sizes and short 
paired-end reads translate to poor alignments in these regions. This coupled with 
conservative thresholds for variant calling by Complete Genomics is the reason for the 
higher number of calls reported using Illumina data. The SNPs Illumina and Complete 
Genomics identified within 5’ UTR occupied 0.3% and 0.08% of the total SNPs.   
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Figure 2 Summary of the variants detected by Illumina and Complete Genomics for (a) 
SNPs (b) Indels. 
 
To further test our methodology, we compared the concordance of the variants 
identified using NGSPE with the variants reported in 1000 genomes, dbSNP and NHLBI 
6500 Exome Sequencing Project (ESP). Phase 1 release of the 1000 genomes variants, 
dbSNP 137 and all variants from the 6500 individuals reported in the NBLBI ESP was 
used for this purpose. The total number of SNPs (QUAL≥50) and number within these 
concordant with each of these databases are reported in Table 8 and Fig. 3. Additionally, 
the ratio of total SNPs to concordant SNPs was calculated (Table 9;Fig. 4) and compared 
with each other. Consistent ratio values across all samples validate the authenticity of the 
pipeline to identify ‘high quality’ variants. 
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Sample NHLBI COUNTS 
1000G 
COUNTS 
dbSNP 
COUNTS 
TOTAL 
SNPS 
02 31594 92556 105210 108781 
03 31601 94686 107957 111975 
04 31541 89539 101684 105344 
02_dup 31596 106091 120428 124920 
03_ dup 31678 100350 114087 118216 
04_ dup 31070 102697 116654 121008 
Table 8: Shows for each publicly available variant database, the number of SNPs that 
match with all SNPs(QUAL>50) in the corresponding sample 
 
 
Figure 3:  Shows for each publicly available variant database, the number of SNPs that 
match with all SNPs(QUAL>50) in the corresponding sample. 
 
Finally, a subset of 47 SNPs within the Consensus Coding Sequence (CCDS) 
region was randomly picked and verified using Sanger Sequencing. Out of the randomly 
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selected point mutations, 15 had quality values between 30 and 50 and 32 had QUAL 
greater than 50. 10 of 15 variants with QUAL scores 30-50 validated and all 32 SNPs 
with QUAL≥50 validated. Based on these results and the concordance rates previously 
reported, we recommend a QUAL threshold of 50 for identifying high quality results. 
Sample NHLBI_RATIO 1000G_RATIO dbSNP_RATIO 
02 0.29 0.85 0.96 
03 0.28 0.84 0.96 
04 0.29 0.84 0.96 
02_dup 0.25 0.84 0.96 
03_dup 0.26 0.84 0.96 
04_dup 0.25 0.84 0.96 
Table 9: Shows for each database, the ratio of number of SNPs present in them with total 
SNPs in the corresponding sample 
 
 
Figure 4: Shows for each database, the ratio of number of SNPs present in them with 
total SNPs in the corresponding sample. 
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3.4. Conclusions and discussion 
With rapid progress in next-generation sequencing technology, a plethora of tools 
have been developed by different research groups to analyze the data generated. 
Consequently, this enabled the development of a variety of analysis pipelines that make 
use of these tools. Here we describe an open-source analytical software pipeline that can 
be used to perform an end-to-end analysis of high throughput genomic sequence data. We 
outline the steps involved in such an analysis process and provide scripts that install the 
required tools and resources and implement the pipeline. These scripts can be run both on 
a single workstation and in a cluster HPC environment.   
Beyond the installation of the variously software required, the tool is designed to 
offer a seamless solution that takes the raw reads in the fastq format as input to provide 
the final list of annotated variants in the VCF format.  This tool is intended not to better 
existing pipelines such as the GATK best practices but provide an implementation of 
such best practices. For example, as we have seen in the flowchart of NGSPE (Fig. 1), 
there are 27 steps required to obtain the annotated list “high quality” variants from the 
fastq files. The details of their order and the actual command are not clearly elucidated in 
articles improving on a pipeline which is what NGSPE aims to show.  
We also evaluated our pipeline by comparing results of blind replicate samples, 
comparing the results using a different pipeline and a different sequencing platform, all of 
which show high concordance rates. When comparing results from our pipeline on exome 
data with results generated using the SOAPsnp pipeline on whole genome data, the CR 
was as high as 97.68% when using a quality score threshold of 50 on both approaches. 
This improved to 98-99% when further raising the quality score threshold. When 
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comparing results for three pairs of duplicates, CRs of 98.63% and 96.17% for SNPs and 
INDELs, respectively, were observed, using quality thresholds of 50. By validating a 
subset of our SNPs across various thresholds of quality using Sanger sequencing we 
estimate that quality thresholds of 50 for SNPs have a very high degree of 
reproducibility. The results indicate that the quality score cutoff value of 50 would be 
suitable for obtaining high quality variants. The CR results for INDELs are ~3% lower 
than for SNPs, suggesting that the pipeline and software packages we used perform better 
for calling SNPs, which could be explained by the complexity of INDELs data.  
Our result indicates that the Illumina platform was able to detect a greater total 
number of variants which is in consistent with Hugo Lam et al.’s report (Lam, et al., 
2012). The reason may be that Complete Genomics had integrated a lot of variants into 
their substitution category, which is more informative and easier for researchers to 
consider adjacent variants all together. As for the genotype quality, our result indicates a 
high concordance rate (99.87% and 98.69% for SNPs and Indels, respectively) of the 
genotype between the two platforms. The results provided in this chapter would help 
researchers make an informed decision about which quality values and sequencing 
platforms best suit their research. The scripts provided are beneficent not only to the wet 
lab scientists interested in analyzing their own data but also to the bioinformaticians 
uninitiated to the complexities of genomic sequence analysis. 
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CHAPTER 4 
 
EXTENSIVE GENETIC CHARECTERIZATION OF MM1R AND MM1S 
IDENTIFIES SEVERAL EVENTS CONTRIBUTING TO DEXAMETHASONE 
RESISTANCE 
 
4.1. Introduction 
 
The treatment paradigm of multiple myeloma has shifted dramatically in the last 
decade. Before this shift occurred, a regimen containing combination Vincristine, 
Adriamycin and Dexamethasone (VAD) was the most commonly prescribed first line of 
therapy to treat Multiple Myeloma (MM) achieving a response rate of 50 – 60% (Wood, 
et al., 1994). However, dexamethasone (Dex) alone is also affective as a single 
therapeutic agent and it accounts for approximately 80% of the effectiveness of VAD 
(Alexanian, et al., 1992). To improve outcomes Dex containing chemotherapy regimens 
are often combined with autologous bone marrow transplantation, yet most patients 
eventually relapse and MM remains essentially incurable (Greenstein, et al., 2003). 
Various alternative therapies exist, in particular IMIDs (thalidomide, lenalidomide, and 
palmolidomide) and proteasome inhibitors (bortezomib and carfilzomib), but inevitably 
they are all combined with glucocorticoids (GC). Therefore, since GC, and principally 
Dex, continue to be the backbone of most myeloma treatment regimens, it is essential that 
we understand the molecular mechanisms that result in Dex resistance.  This is a critical 
step for improving current therapeutic approaches using glucocorticoids (GC). 
The precise method of action of glucocorticoids in not known in multiple 
myeloma. Various groups studying hematologic malignancies have shown glucocorticoid 
receptor (GR) expression is essential for GC response (Greenstein, et al., 2002; Grugan, 
et al., 2008; Sanchez-Vega and Gandhi, 2009; Sharma and Lichtenstein, 2008). 
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Moreover, decreased expression of the GR correlate with decreased response to GC, and 
restoration of GR in cell lines that lack it restores partial GC response (Sharma and 
Lichtenstein, 2008). This suggests that GC response is directly associated with GR 
expression but further data suggests that additional molecular mechanisms could 
potentially play a role in GC resistance in MM cell lines. To support this assumption, 
mutations in GR, reduced expression of the GR, and overexpression of GR inhibitor 
microRNA have been linked to GC resistance in other models (Greenstein, et al., 2002; 
Schmidt, et al., 2004; Tessel, et al., 2011). 
Here we report a comprehensive genetic characterization of the Isogenic MM cell 
lines MM1S and MM1R developed by Rosen et al (Greenstein, et al., 2003). These cell 
lines were derived from MM.1 (Goldman-Leikin, et al., 1989) and can be distinguished 
by their sensitivity (MM1S) and resistance (MM1R) to Dex. MM1R was derived from 
MM.1 by selection for Dex resistance, while MM1S represents a single cell clone from 
MM.1 with sensitivity to Dex. Despite their differences in response to Dex, flow 
cytometry analysis showed the same cell surface markers and cell lines are 
immunocytochemically identical (Greenstein, et al., 2002). Therefore, suggesting this 
isogenic series of cell lines derived from MM.1 are ideal to study causal events of Dex 
resistance since the cells share a common genetic background and differ only in their 
resistance to Dex (Greenstein, et al., 2002). 
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4.2. Materials and methods 
 
4.2.1. DNA and RNA extraction 
MM1S and MM1R cell lines were purchased from ATCC. The cell lines were established 
in the lab according to ATCC recommendations for propagation and preservation. 
Subsequently growth was recommended from the recommended RPMI1640 + 10% FBS 
to Advanced RPMI1640 + 4% FBS after showing no effects in growth parameters. Cells 
were harvested from cultures 3 days after seeding at 400,000 cells/ml. 
DNA was isolated from 5 x 106 cells using the Qiagen Gentra Puregene method (Qiagen). 
DNA pellets were thoroughly dried, and resuspended in TElowE (10mM Tris, 0.1mM 
EDTA, pH8) (Teknova). Final DNA concentration was diluted into the range of 50ng/ul 
– 200ng/ul, and quantified by Nanodrop 1000 spectrophotometer (Thermo Scientific) 
quantitation and final double stranded concentrations were determined using the Broad 
Range assays on the Qubit fluorometer(Life Technologies). Additionally 100-200ng of 
each sample was run on an analytical gel (0.8% Agarose TAE) to assess the quality of the 
material. Only high molecular weight DNA samples were moved forward into 
sequencing libraries. DNA samples were stored at 4C, or -20C for long-term storage. 
RNA was isolated from 5 x 106 cells resuspended in 1mL of TRIzol reagent (Life 
Technologies) and then stored at -80C until isolation. To isolate RNA we added 200ul of 
chloroform to room-temperature TRIzol suspensions and after centrifugation the upper 
aqueous phase was mixed 50/50 with 70% ethanol and applied to a Purelink RNA 
Isolation column (Life Technologies), following the recommended wash steps an 
optional on-column DNase treatment (Ambion) was performed. RNA was eluted from 
the columns in 75ul of RNase/DNase-free water and stored immediately on ice. RNA was 
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quantified by a Nanodrop 1000 spectrophotometer (Thermoscientific) to determine 
concentration and a RNA6000 BioAnalyzer chip (Agilent) to determine the RIN. Only, 
samples with RIN greater than 9 were moved forward into sequencing libraries. 
 
4.2.2. RNA library construction and sequencing 
 
We constructed paired-end mRNA libraries from 2ug of total RNA following the TruSeq 
RNA Sample Preparation v2 Guide, Revision A (Illumina). Libraries were amplified for 
10 PCR cycles (instead of the recommended 15 cycles). Final libraries were quantified by 
DNA 1000 chip (Agilent), Qubit DNA Broad Range (Life technologies), and qPCR 
(Kapa), and were diluted to less than 50,000pM by Qubit Broad Range quantitation. Final 
library size (mode) fell between 260 and 280bp. 
Libraries were pooled and sequenced on the Illumina2000 HiSeq platform, using 
v3 chemistry (one TruSeq PE Cluster Kit, and three TruSeq SBS 50-cycle HS kits per 
flow cell) (Illumina) to produce 83 x 83 paired end reads. 
4.2.3. Whole exome and long-insert whole genome library construction and 
sequencing 
Whole genome libraries for exome capture were constructed from 3ug genomic DNA 
following the SureSelect XT for Illumina PE v1.2 Kit (Agilent), with SureSelect XT 
70mb capture using V4+UTR capture oligos (Agilent). Libraries were pooled following 
capture, and amplified for 12 PCR cycles. Final libraries were quantified by High 
Sensitivity DNA chip (Agilent), and Qubit DNA High Sensitivity kit (Life 
Technologies). Pools averaged between 3000 and 8000pM, with an average library size 
(mode) around 360bp. 
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Whole genome long insert libraries were constructed from 1ug genomic DNA 
following the Kapa Library Prep Kit with Standard PCR Amplification, using TruSeq 
DNA indexed adapters (Illumina). Fragmentation conditions were modified for a 1Kb 
target insert size (on the Covaris E210 in a microtube plate: Duty Cycle 2, Intensity 6, 
Cycles/burst 200, Time 20 seconds). Samples were amplified for 5 cycles, size selected 
by agarose gel punch, and cleaned up by QIAquick gel extraction kit (Qiagen). Libraries 
were pooled, and quantified by High Sensitivity DNA chip (Agilent), and Qubit DNA 
High Sensitivity kit (Life Technologies). Pool was 5400pM by Qubit, with an average 
library size (mode) around 1333bp. 
Capture pools were sequenced on the Illumina 2000 HiSeq platform, using v3 
chemistry (one TruSeq PE Cluster Kit, and one TruSeq SBS 200-cycle HS kit per flow 
cell) (Illumina) to result in 100 x 100 paired ends reads.  
4.2.4. The RNA sequencing data processing pipeline 
The multiplexed samples were converted to demultiplexed Fastq format using 
Illumina’s ‘bcl2fatsq’. One BAM file per sample is created by merging aligned bams at 
the lane level using Tophat 2.0.4(Trapnell, et al., 2009). The reads are aligned initially to 
the known transcripts (Ensembl 64) followed by aligning the unmapped reads to the 
Human reference genome GRCh37. Inner mate distance and standard deviations is a 
required parameter to provide to Tophat for alignment. This is calculated by aligning the 
first 5 million reads to the human transcriptome reference GRCh37.64 from Ensembl. 
Picard is used to obtain the inner mate distance and standard deviation of fragment 
lengths. The read length is estimated dynamically and an appropriate number of 
mismatches to allow for alignment is determined.  
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In our tests with aligning reads using Tophat 2.0.4 (Trapnell, et al., 2009), we 
found that as read length increases, allowing more mismatches gives substantial 
improvement in number of mapped reads with only a marginal drop in the percentage of 
unique reads mapped. For 83 bp paired-end data we found optimal alignment rates when 
allowing 4 mismatches per read. This is elucidated in the figure 1. Hence, 4 mismatches 
were allowed during alignment. 
 
Figure 1: X-axis shows the number of mismatches while Y-axis shows ratio of mapped 
reads. The first column of figures show that as read length increases, the number of 
mapped reads increase by allowing greater number of mismatches per read. The second 
column shows that percentage unique reads remain constant showing that the additional 
reads aligned with increasing number of mismatches are indeed unique and not the same 
read mapping at multiple places. 
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Subsequently, the expression estimates are obtained using Cufflinks (Trapnell, et 
al., 2012). Expression estimates were guided by providing the reference transcriptome, 
Ensembl v64.  
Immunoglobulin genes in Myeloma are abundantly expressed across all samples 
and it is computationally time complex to estimate their abundance. Hence, the IgH locus 
genes are provided in a mask file for cufflinks to mask for gene-expression estimation. 
Numbers of reads that map to each gene are also obtained using HTSeq, for each of the 
samples run as triplicates, by providing known human transcripts GRCh37.64.  
Differential expression testing on these obtained counts were obtained using DESeq 
(Anders and Huber, 2010). 
 
4.2.5. The exome sequencing data processing pipeline: The multiplexed samples were 
converted to a FASTQ format using Illumina’s software ‘bcl2fatsq’. One BAM file per 
sample is created by merging aligned bams at the lane level using BWA(Li and Durbin, 
2010) to the human reference genome GRCh37. Each of the bam files is then processed 
as per the steps given below. 
Quality control: We verified the concordance of the MM.1S and MM.1R genotypes 
using snpSniffer. The concordance rates for these RNA-Seq and exomes samples was at 
least 0.97 for each sample pair, confirming these files originate from the same individual. 
Marking Duplicates: All PCR duplicates but one that mapped to the exact same 
coordinate on the genome were marked such that they were excluded from further 
analysis. This was done using Picard. 
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Indel Realignment: Mapped reads that harbor small insertions and deletions were jointly 
realigned to reduce false positive variant calls due to misaligned reads. The misalignment 
events usually occur at highly repetitive, low complexity regions causing some indels to 
be placed inconsistently. The Indel realigner using GATK(McKenna, et al., 2010) locally 
realigns these Indels such that all Indels within a certain genomic region are mapped to 
the same loci. 
Base Recalibration: The phred quality score associated with each base is recalibrated 
using GATK(McKenna, et al., 2010) taking into account the read cycle, the lane, the tile 
and the preceding base of the base to be recalibrated. 
Variant Calling and Annotation: Single nucleotide somatic substitutions were detected 
with MuTect (Cibulskis, et al., 2013) and short Indels were called using Samtools (Li, et 
al., 2009). Mutect was run using two different configurations (Table 1; Fig. 2):  
1) To identify mutations unique to MM1S and MM1R, each of the 
individual bams are provided as a tumor-normal pair with the 
other. 
2) Each of the samples were run by themselves and a subtractive list 
of mutations were identified. 
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Figure 2: Shows overlap of SNVs in MM1R and MM1S by two different configurations 
of variant calling used. 
 
Type MM1R Paired 
MM1R 
Single 
MM1S 
Paired 
MM1S 
Single 
Expressed (S+NS) 52 1172 58 1020 
Expressed (NS) 13 176 22 156 
Expressed and 
mutation present in 
RNA (S+NS) 
35 795 46 714 
Expressed and 
present in RNA (NS) 11 132 19 122 
Table 1: Gives number of somatic SNV’s by type identified by two configuration 
approaches used for each cell line 
 
 
  62 
The somatic substitutions were restricted to the exonic space defined by RefSeq 
or GENCODE and targeted by Agilent SureSelect V4 + UTR capture kit. Remaining 
SNVs were filtered to include only those mutations with an allele fraction of at least 10%. 
Further filtering was applied to exclude mutations also found in any of dbSNP, NHLBI 
and 1000 genomes databases with a global minor allele frequency greater than 0.1% in 
each.   
Similarly, Indels identified by Samtools were restricted to the exonic space as 
previously described followed by excluding Indels found in dbSNP, NHLBI and 1000 
genomes databases with a global minor allele frequency less than 0.1% in each. 
Annotation of the mutations was done using SnpEff for all the available transcripts from 
Ensembl 64.  
 
4.2.6. The long-insert whole genome sequencing data processing pipeline: Aligned 
reads in SAM format were obtained as previously described for MM1R and MM1S but 
also Hapmap control samples GM15510 and GM12878. Structural somatic variations 
were identified using an internal tool at TGen between a) MM1R as tumor and MM1S as 
normal b) MM1S as tumor and MM1R as normal c) MM1R as tumor with either 
GM15510 and GM12878 as control d) MM1S as tumor with either GM15510 and 
GM12878 as control. When Hapmap samples were used as “normal” samples, only those 
structural variants common to either Hapmap samples were included.  
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4.2.7. Genome-wide Methylation 
We measured DNA methylation using the Infinium HumanMethylation450 BeadChip 
Array. The assay contains 485,764 probes that recognize CpG and CpNpG sites, CpG 
islands/shores/shelves/open sea, non-coding RNA (microRNAs and long non-coding 
RNAs), and sites surrounding transcription start sites for coding genes and also for 
corresponding gene bodies and 3’-UTR. In addition, probes were designed to target 
intragenic regions derived from GWAS studies. The array covers 99% of RefSeq genes 
and 96% of known CpG islands and coverage averages 17 CpG sites/gene region 
distributed across the promoter, 5’-UTR, first exon, gene body and 3’-UTR.  
Each sample underwent bisulfite conversion using 1 ug gDNA using the EZ DNA 
methylation kit according to the manufacturer’s recommendation for the Illumina 
Infinium Assay. Bisulfite-treated DNA was then hybridized to arrays according to the 
manufacturer’s protocol. We used GenomeStudio V2011.1 (Illumina) for methylation 
data assembly and acquisition. Methylation levels for each CpG residue are presented as 
β values, estimating the ratio of the methylated signal intensity over the sum of the 
methylated and unmethylated intensities at each locus. The average β value reports a 
methylation signal ranging from 0 to 1 representing completely unmethylated to 
completely methylated, respectively. All probes with detection p-values >0.05 were 
removed. Identification of differentially methylated probes was determined by calculating 
delta beta values for each array probe. Only sites with delta beta values ≥0.2 or ≤-0.2 
between MM1.S and MM1.R cell lines and which passed false discovery rate correction 
(p<0.05) were retained for further analysis. 
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4.2.8. aCGH data analysis pipeline: Agilent feature extraction was used to process 
microarray images to obtain feature intensities and ratios. GC correction, fuzzy zero, 
centralization and replicate probe averaging was applied using Agilent Genomic 
Workbench. Smoothing and applying the Circular Binary Segmentation (CBS) algorithm 
was then done using DNAcopy R package(Seshan and Olshen, 2011). The minimum 
number of probes for a changed segment for cell lines and patients is 2 probes. 
 
4.3. Results 
Results for all the individual assays are provided in the phase 1 section of the results. 
Overview of the analysis in phase 1 is shown in figure 3. A summary of all the genetic 
aberrations, unique to each of the cell line, MM1.R and MM1.S is provided in Figure 3. 
A comprehensive genomic profile of each of the cell line is provided in figure 3 and 4. 
An integrative analysis of these phase 1 results looking for genes in the apoptotic and 
drug resistance pathways are provided in phase 2. 
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4.3.1 Phase 1 Analysis 
 
Figure 3: Pipeline overview of analysis done as part of phase 1 is shown. 
 
4.3.1.1. aCGH: 377 genes were identified with aberrations unique to MM1R. Of these, 
272 genes (including NR3C1) had deletions, while 105 had copy number gains. MM1S 
had 1254 genes with aberrations, all being deletions. 
 
4.3.1.2. Exomes 
SNVs: In all, 2954 SNV’s in 2847 genes were identified in MM1R and MM1S. These 
included synonymous and non-synonymous SNPs after the SNP filtering described in the 
methods section. Out of 2954 SNVs, 1864 were common to both cell lines while 760 
mutations were unique to MM1R and 330 mutations were unique to MM1S. Running 
MM1R and MM1S cell lines as tumor/normal pairs identified 134 mutations each in 
either direction (Fig. 2). To find the most deleterious mutations, which potentially confer 
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resistance, we filtered the mutation list to those genes which are both expressed in RNA 
(FPKM>=5) and the mutated allele is detected in the matched RNA. This filtering 
brought down the number of unique mutations to 132 and 122 in MM1R and MM1S 
respectively. 
Indels: Samtools identified a total of 3539 Non-Synonymous and Synonymous Indels in 
both samples. Out of these, there were 3028 Indels in MM1R and 2837 in MM1S with 
2326 common to both. Filtering for Synonymous Indels left a total of 254 and 233 Non-
Synonymous Indels in MM1R and MM1S respectively. Finally, we looked for non-
synonymous indels that are present in genes that are expressed in RNA (FPKM>=5) and 
identified 115 and 100 indels in MM1R and MM1S respectively. 
 
Type MM1R_Single MM1S_Single Common to both 
NS+S 3028 2837 2326 
NS 254 233 189 
Expressed (NS) 115 100 81 
Table 2: Gives number of somatic Indel by type for each of the MM1 cell lines. 
 
4.3.1.3. RNA-Seq: Differential expression testing using DESeq (Anders and Huber, 
2010) on each cell line run as triplicate identified 1182(FDR p-value <0.05) differentially 
expressed genes out of which 577 were down-regulated in MM1R where as 605 genes 
were significantly up-regulated. The top 25 upregulated and down-regulated genes in 
MM1R are shown in figure 4. 
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Figure 4: (a) Shows FPKM values for top 25 genes significantly down-regulated genes 
in MM1R. (b) Shows FPKM values for top 25 genes significantly up-regulated genes in 
MM1R. 
 
4.3.1.4. Long insert whole genomes: Using the Hapmap samples as “controls”, a total of 
55 structural variations were identified in MM1R while 57 aberrations were identified in 
MM1S. Using MM1R as tumor and MM1S as control, a total of 13 variants were 
identified where as 7 variants were identified using MM1S as control.  
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Figure 5: Shows genomic profile for MM1R using exome sequencing, RNA-Seq aCGH 
arrays and whole genome long-insert sequencing. Genes in black on the outer ring 
represent non synonymous mutations in them with FPKM < 5 while red represent non 
synonymous mutations with FPKM >= 5. Inner ring in grey shows copy number losses in 
green and copy number gains in red. Links shown in green are inter-chromosomal 
aberrations while links shown in blue are intra-chromosomal aberrations 
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Figure 6: Shows genomic profile for MM1S using exome sequencing, RNA-Seq aCGH 
arrays and whole genome long-insert sequencing. Genes in black on the outer ring 
represent non synonymous mutations in them with FPKM < 5 while red represent non 
synonymous mutations with FPKM >= 5. Inner ring in grey shows copy number losses in 
green and copy number gains in red. Links shown in green are inter-chromosomal 
aberrations while links shown in blue are intra-chromosomal aberrations 
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Figure 7:Shows aberrations unique to each cell line MM1R/MM1S.Genes labeled in red 
in the outer ring are unique non-synonymous mutations that are expressed in MM1S. 
Genes in black are the same in MM1R. Moving inwards, Ring 1) Shows all unique 
mutations in MM1S in purple and those in MM1R in blue. Ring 2) Shows downregulated 
genes in MM1R in yellow and upregulated genes blue. Ring 3) Shows copy number gains 
unique to MM1R in red and losses in green. Ring 4) Shows copy number losses unique to 
MM1S. Purple links show translocations unique to MM1R in purple and those unique to 
MM1S in blue. 
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4.3.2 Phase 2 Analysis: 
 
Figure 8: Overview of analysis done as part of Phase 2 is shown. 
 
An abnormality in the glucocorticoid receptor NR3C1 is known to exist in the MM1R 
cell line (Moalli, et al., 1992). Our analysis showed this abnormality is a complex set of 
overlapping deletions resulting in downregulation of RNA expression of NR3C1 and a 
fusion of NR3C1 with ARGEF (Fig 4(b), Fig 9). Further, we looked at events unique to 
MM1R, identified by assays mentioned above, to identify putative events responsible for 
resistance. We concentrated on aberrations in genes that were previously reported to be 
involved in drug resistance.
! SNV 
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Figure 9: a) shows evidence for deletion in the NR3C1 gene in MM1R through absence 
of reads in whole genome long insert sequencing data b) shows overlapping discordant 
read pairs in blue confirming the homozygous deletion. 
 
Interestingly, we identified a missense mutation in ABCB11. Ling et al (Childs, et 
al., 1998) reported taxol resistance mediated by transfection of ABCB11. Aberrant 
upregulation of the ABCG2, which was reported to confer drug resistance in other 
cancers(Allikmets, et al., 1998; Doyle, et al., 1998), and a corresponding hypo-
methylation of ABCG2, suggests identification of key events responsible for drug 
resistance in MM1R. HCN2 amplification, hypo-methylation and overexpression, 
HDAC4 and NPPC deletion and its down regulation are other significant events. 
In the apoptotic pathway, deletion and downregulation of NR3C1, ING5, CXCR7, 
PDCD1; mutation and upregulation of PLK5; missense mutation, hypo methylation and 
upregulation of ROBO2, UTR 3’ and 5’ mutations, hypo-methylation and down 
regulation of TLE1 are significant aberrations.  HSPB1, previously reported(Chauhan, et 
al., 2003) to be in elevated levels in Dex resistant lines is also significantly upregulated in 
MM1R.  
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4.4 Conclusions and Discussion 
Response efficacy of VAD (Wood, et al., 1994), thalidomide plus Dex(Weber, et al., 
2003) as first-line treatments and Lenalidomide plus Dex(Weber, et al., 2007) for 
relapsed patients underscores the importance of Dex for MM treatment.  Thalidomide and 
its analogs are reported to have overcome resistance to Dex(Hideshima, et al., 2000), yet 
molecular mechanisms for modes of action of Thalidomide or how it overcomes Dex-
resistance is unclear.  
Understanding events responsible for the cause of resistance is essential for 
identifying alternative treatments for patients resistant to Dex. Moreover, this is 
increasingly important as we move towards patient specific treatments of Myeloma. 
Here, we present a comprehensive genomic characterization of MM1R and 
MM1S and validated previously reported deletion in NR3C1. Previously reported 
upregulation of HSPB1 in Dex resistant lines are also found in MM1R. In addition, we 
report aberrant genetic events in the ABC transporter genes and genes involved in cell 
apoptosis including ABCB11, ABCG2, ING5, CXCR7, PDCD1, PLK5, ROBO2 and 
TLE1 among others. 
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CHAPTER 5 
 
COMPREHENSIVE GENOMIC CHARECTERIZATION OF ALL COMMERCIALLY 
AND NON-COMMERCIALLY AVAILABLE HUMAN MYELOMA CELL LINES 
 
Abstract 
Human myeloma cell lines (HMCL) provide both a discovery and validation platform to 
improve our understanding of the molecular pathogenesis of multiple myeloma. Here, we 
present genomic characterization of 69 multiple myeloma cell lines using exome 
sequencing, RNA-Seq and aCGH. In addition to the known aberrations in NRAS, KRAS, 
TP53, TRAF3 and DIS3 previously reported in myeloma, we reveal new genetic 
aberration in KDM6B, RB1, MAP3K1, MLL3, PRKDC and PTPRB implicated in other 
cancers through our novel integrative analysis methodology. We show that KDM6A 
deletions are overrepresented in cell lines and identify Wnt signaling pathway as a target 
for such inactivation events. Since cell lines are commonly used as in vitro models, we 
define cell lines that best represent patients based on common lesions identified through 
our integrative analytical approach. Lastly, we make the results a public resource though 
a searchable web portal called myelomagenomics.tgen.org. The findings presented in this 
study help explain the genetic complexity underlying this deadly disease and will greatly 
advance such knowledge. 
5.1 Introduction 
Human immortal cell lines have proven to be accessible biological models for 
discovery, validation, and improving our understanding of the etiology of diseases. Cell 
lines have been instrumental in such discoveries due the virtually infinite amount of 
material required for various tests, which could be impossible using tissue samples from 
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patients. Cell lines also have been invaluable to study the efficacy of novel drugs that 
cannot be tested on patient samples directly. 
The HeLa cell line was the first human cell line established in 1952 and has 
become the most widely used cell line since(Gey, et al., 1952). Some of the most 
significant discoveries from HeLa cell line alone is the development of the polio 
vaccine(Scherer, et al., 1953), the establishment of a link between the cervical cancer and 
Human Papilloma Virus (HPV) and the role of telomeres in preventing chromosome 
degradation(Landry, et al., 2013).  
More recent advances in cancer genomics, and specifically targeted therapy based 
on specific genetic aberrations, have fueled the need for cell lines as a platform to explore 
the efficacy of novel anti-cancer agents. The cancer genomics community has 
acknowledged the importance of cell lines in bettering our understanding of cancer and 
drug efficacy through large scale cell line characterization projects such as the NCI 60 
cell line project, Cancer Cell Line Encyclopedia (CCLE) and the Sanger Institutes Cancer 
Cell Line project. As part of the CCLE, 947 commercially available cell lines across 
different cancers have been genetically characterized along with a 24 compound drug 
screen across 479 of these(Barretina, et al., 2012). NCI60, which initially started off as a 
cell line panel for anti-cancer drug screening in the late 1980s, has since been 
characterized using exome sequencing, SNP and gene expression arrays(Abaan, et al., 
2013; Blower, et al., 2007; Bussey, et al., 2006; Garraway, et al., 2005; Ikediobi, et al., 
2006; Ross, et al., 2000; Shoemaker, 2006). The Sanger Institute Cell Line project also 
sequenced  ~600 genes of over 1015 cell lines from non-commercial and commercial 
repositories.  
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These cell line characterization efforts led to significant findings and improved 
outcomes in patients. Some of the most significant include the novel amplifications 
identified in MITF in melanoma cell lines, which are prevalent in the metastatic disease 
and correlated with decreased patient survival(Garraway, et al., 2005). Cell lines also 
provided a validation platform for two independent mutations identified in the promoter 
of TERT in melanoma samples. Beyond biological discovery, cell lines were 
instrumental in identifying Thiosemicarbazone to treat Multi Drug Resistant (MDR) 
tumor cell populations(Shoemaker, 2006).  
Human Myeloma Cell Lines (HMCL) have also played a pivotal role in 
identifying novel aberrations and subtypes, along with providing support for identifying 
novel drugs to treat Myeloma. The most significant findings from the use of myeloma 
cell lines has been the identification of recurrent IGH switch translocations in 
myeloma(Bergsagel, et al., 1996), a finding that was subsequently used to classify the 
subtypes in myeloma. Myeloma cell lines were significant in their contribution for the 
approval of use of Bortezomib in MM(Shoemaker, 2006). Through the above mentioned 
examples, the utility of cell lines and the benefit of genomic characterization of them is 
evident.  
Barring the 25 commercially available cell lines that were characterized as part of 
CCLE using a 4.5Mb custom capture DNA sequencing, gene expression arrays and SNP 
arrays, no previous study has comprehensively characterized all multiple myeloma cell 
lines. In this study, we have characterized 69 commercially and non-commercially 
available myeloma cell lines (Table 1) using WES, RNA-Seq and aCGH. Further, we 
applied a novel integrative analysis methodology to glean new knowledge of the etiology 
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of myeloma. Through our analysis methodology we also identified cell lines best 
representative of patient samples based on common lesions in myeloma. We also 
identified KDM6A deletions to be overrepresented in HMCL and have identified 
downstream targets of such aberrations. Lastly, for the benefit of the multiple myeloma 
community we made this resource publicly available through 
myelomagenomics.tgen.org. 
 
Cell Lines Source 
MM1R, MM1S, RPMI8226, U266 ATCC 
AMO1, COLO677, EJM, JJN3, Karpas620, L363, LP1, 
MOLP2, MOLP8, NCIH929, OPM2, SKMM2 DSMZ 
JIM1, JIM3, Karpas25, Karpas417, Karpas929, Karpas929 ECACC 
Delta47, FLAM76, KHM1B, KMM1, KMS11, KMS11, 
KMS12BM, KMS12PE, KMS20, KMS21BM, KMS26, 
KMS27, KMS28BM, KMS28PE, KMS34, PCM6 
 
JCRB 
ALMC1, ALMC2, ANBL6, DP6, JMW1, KAS61, KP6, 
VP6 
 
Diane Jelinek 
ALMC1, ALMC2, ANBL6, ARD, ARP1, CAG, FR4, 
H1112, INA6, JK6L, KHM11, KMS18, MMM1, OCIMY1, 
OCIMY5, OCIMY7, OH2, OPM1, PE1, PE2, SKMM1, 
UTMC2, XG1, XG2, XG6, XG7 
Leif Bergsagel 
Table 1: Shows the list of all cell lines that were characterized along with the source they 
were obtained from. 
 
5.2. Methods and Materials 
 
5.2.1. DNA and RNA extraction 
The commercially available cell lines were purchased from American Type Culture 
Collection (ATCC), Deutsche Sammlung von Mikroorganismen und Zellkulturen 
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(DSMZ), European Collection of Cell Cultures (ECACC) and Japanese Collection of 
Research Bioresources (JCRB). The non-commercially available cell lines were kindly 
provided by Drs. Lief Bergsagel (Mayo Clinic Arizona) and Diane Jelinek (Mayo Clinic 
Rochester). The commercially available cell lines were established into the lab using the 
suppliers’ instructions for propagation and preservation, with the exception of using FBS 
that was not heat-inactivated and glutamax in place of L-glutamine.  After establishment 
commercially available cell lines were tested for growth differences between the 
recommended media and Advanced RPMI1640 + 4% FBS supplemented with 1x 
Glutamax.  In all cases no significant differences were observed and thus this universal 
media was used to grow each cell line for characterization.  
DNA was isolated from 5 x 106 cells using the Qiagen Gentra Puregene method 
(Qiagen). DNA pellets were thoroughly dried, and resuspended in TElowE (10mM Tris, 
0.1mM EDTA, pH8) (Teknova) instead of the provided DNA suspension buffer. Final 
DNA concentration was diluted into the range of 50ng/ul – 200ng/ul based on Nanodrop 
1000 spectrophotometer (Thermo Scientific) quantitation and final double stranded 
concentrations were determined using the Broad Range assay on a Qubit fluorometer 
(Life Technologies). Additionally 100-200ng of each sample was run on an analytical gel 
(0.8% Agarose TAE) to assess the quality of the material. Only high molecular weight 
DNA samples were moved forward into sequencing libraries. DNA samples were stored 
at 4C, or -20C for long-term storage. 
RNA was isolated from 5 x 106 cells resuspended in 1mL of TRIzol reagent (Life 
Technologies) and then stored at -80C until isolation. To isolate RNA, 200ul of 
chloroform was added to room-temperature TRIzol suspensions and after centrifugation 
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the upper aqueous phase was mixed 50/50 with 70% ethanol and applied to a Purelink 
RNA Isolation column (Life Technologies), following the recommended wash steps an 
optional on-column DNase treatment (Ambion) was performed. RNA was eluted from 
the columns in 75ul of RNase/DNase-free water and stored immediately on ice. RNA was 
quantified by a Nanodrop 1000 spectrophotometer (Thermoscientific) to determine 
concentration and a RNA6000 BioAnalyzer chip (Agilent) to determine the RIN. Only 
samples with RIN greater than 9 were moved forward into sequencing libraries. 
5.2.2. RNA Library Construction and Sequencing:  
 
Paired-end mRNA libraries were constructed from 2ug of total RNA following the 
TruSeq RNA Sample Preparation v2 Guide, Revision A (Illumina). Libraries were 
amplified for 10 PCR cycles (instead of the recommended 15 cycles). Final libraries were 
quantified by DNA 1000 chip (Agilent), Qubit DNA Broad Range (Life technologies), 
and qPCR (Kapa), and were diluted to less than 50,000pM by Qubit Broad Range 
quantitation. Final library size (mode) fell between 260 and 280bp. 
Libraries were pooled and sequenced on the Illumina HiSeq 2000 platform, using 
v3 chemistry (one TruSeq PE Cluster Kit, and three TruSeq SBS 50-cycle HS kits per 
flow cell) to generate 83 x 83 bp paired end reads.  
 
 5.2.3. Whole Exome Library Construction and Sequencing:  
 
Whole genome libraries for exome capture were constructed from 3ug genomic DNA 
following the SureSelect XT for Illumina PE v1.2 Kit (Agilent), with SureSelect V4 + 
UTR (70Mb) capture oligos (Agilent). Post capture libraries were amplified with 12 PCR 
cycles. Final libraries were quantified by High Sensitivity DNA chip (Agilent), and Qubit 
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DNA High Sensitivity kit (Life Technologies). Sequencing pools averaging between 
3000 and 8000pM were created with 6 samples each, with an average library size (mode) 
around 360bp. 
Pools were sequenced on the Illumina2000 HiSeq platform, using v3 chemistry 
(one TruSeq PE Cluster Kit, and one TruSeq SBS 200-cycle HS kit per flow cell) to 
result in 100 x 100 paired end reads.  
 
5.2.4. The RNA sequencing data processing pipeline 
The multiplexed samples were converted to de-multiplexed reads in FASTQ 
format using Illumina’s ‘bcl2fatsq’. Demultiplexed paired-end reads were then merged 
for each sample to obtain one pair of Fastq’s for each sample followed by aligning these 
reads using STAR(Dobin, et al., 2013) aligner. The reads were aligned by providing 
known transcripts (Ensembl 70) and the Genome Reference Consortium human build 37  
(GRCh37) reference including the version 5 decoy sequences used by the 1000 genomes 
project. The median number of reads produced per sample was 142.3 million with 
median alignment rates of 97.05%(Fig. 1). 
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Figure 1:Shows number of reads obtained after sequencing and their alignment rates to 
the genome and immunoglobulin locus. 
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Figure 2: Shows the overview of RNA-Seq pipeline 
 
Gene expression estimates in FPKM (fragments per kilobase of exon per million 
fragments mapped) are obtained using Cufflinks 2.1.1 (Trapnell, et al., 2012) by 
providing the known transcripts from Ensembl 70. Gene-level raw counts were obtained 
using HTSeq(Anders, 2010) by providing the known Ensembl 70  transcripts. Expression 
estimates were then obtained by normalizing the read counts using DESeq(Anders, 
2010). 
In our preliminary testing, Tophat-Fusion had the best performance in terms of 
validation rates of the fusions identified in our test cohort. Four commonly used gene-
fusion detection algorithms were tested including Tophat-Fusion, Chimerascan, deFuse 
and Snowshoes. Hence, Tophat-Fusion(Kim and Salzberg, 2011) was used to identify 
fusions across all cell lines. To reduce potential false positives due to long-distance 
splicing events, only inter-chromosomal events were included in our final list of fusions. 
! READ1.FQ READ2.FQ 
TOPHAT FUSION 
STAR ALIGNMENT 
HTSEQ FILTER CUFFLINKS 
DESEQ NORMALIZE FILTERED FUSIONS TRANSCRIPT FPKM GENE FPKM 
CLUSTERING 
hs37d5.fa + 
RNA18S5 & 28S 
hs37d5.fa + 
RNA18S5 & 28S 
Ensembl 70 
Ensembl 70 
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Further, only those fusions which have evidence of at least 2 spanning reads, spanning 
mate pairs and spanning mate pairs where one end spans a fusion were included.  
Additional filtering was applied to exclude all but one fusion per gene per cell line with 
the highest reported score. Figure 2 shows list of all fusions involving the same gene in 
more than 1 cell line. The overview of the pipeline is shown in figure 2. 
 
Figure 3: Shown in blue are fusions involving the same gene in more than 1 cell line but 
less than 5 cell lines. Shown in red are fusions involving WHSC1 which was identified in 
14 cell lines 
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5.2.5. Unsupervised hierarchical clustering of Patient and Cell lines: Gene level raw 
read counts were obtained using HTSeq(Anders, 2010) for cell lines and patients 
providing the Ensembl 70 known transcripts database. Raw read counts were then 
normalized using DESeq(Anders, 2010) which were transformed to a logarithmic scale. 
Features having a raw read count of 10 or less across all features were excluded from 
further analysis. The top 700 genes with the highest standard deviation were used for 
unsupervised hierarchical clustering. 1 - p (p is the Pearson’s correlation coefficient) was 
used as the distance metric and Ward’s agglomeration method was used for clustering. 
Additionally, features corresponding to the 50 upregulated and downregulated genes for 
each MM subtype from a SAM-PAM classifier identified by Zhan et al(Zhan, et al., 
2006) were obtained. Unsupervised hierarchical clustering was applied as described 
above. 
 
5.2.6. Defining outlier expression of genes: To define genes with outlier expression that 
commonly occurs in Myeloma due to IGH rearrangements, we followed Chinnaiyan et 
als COPA methodology(Rubin and Chinnaiyan, 2006). Basically, we obtained the FPKM 
values for all genes across all cell lines and centered the expression using the median. 
Next, we obtained the Median Absolute Deviation (MAD) and scaled the expression 
values. Subsequently, thresholds for defining outliers were defined on the transformed 
expression by using a 75th percentile + Inter Quartile Range (IQR) cutoff. Samples are 
flagged as having outlier expression of a certain gene if their transformed expression 
value surpasses the defined threshold.  
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Let xij be the expression values for genes where i = 1,…., n and genes j = 1,….,p. Here, 1, 
…, n are all cell lines.  
Standardizing the data, we have 
𝑥!" =   𝑥!"   −   𝑚𝑒𝑑!"𝑚𝑎𝑑!  
 madj =  1.4826 x mediani=1,...,n (|xij −  medj |), 
In the above equation 1.4826 makes madj  approximately equal to the standard error for 
normally distributed random variables(Wu, 2007). 
 
Then the threshold for a particular gene is defined as 75th percentile + IQR. All samples 
that have transformed expression value for gene j above the threshold are defined as 
outliers.  
 
5.2.7. The exome sequencing data processing pipeline:  
The multiplexed samples were converted to a FASTQ format using Illumina’s software 
‘bcl2fastq’. One BAM file per sample was created by merging aligned bams at the lane 
level using BWA-0.5.9(Li and Durbin, 2009) to the human reference genome GRCh37. 
The median target coverage across all samples was 95.73x and the percentage of all 
target bases achieving 30x coverage is 83.86%(Fig. 2).Each of the bam files is then 
processed as per the steps given below. A high level overview of these steps is shown in 
Fig. 8. 
 
 
  86 
Quality control: We verified the sample concordance using “snpSniffer” by comparing 
the genotypes of the curated positions across all samples sequenced in Dr. Keats 
laboratory. The concordance rates for these samples between RNA-Seq and exomes was 
atleast 0.84 for each sample pair. 
Marking Duplicates: All PCR duplicates but one that mapped to the exact same 
coordinate on the genome were marked such that they were excluded from further 
analysis. This was done using Picard. The median percentage of the aligned reads that 
were duplicates was 13.44%(Fig. 4). 
 
Figure 4: Shows target coverage and duplication rates across all samples.  
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Indel Realignment: Mapped reads that harbor small insertions and deletions were jointly 
realigned to reduce false positive variant calls due to misaligned reads. The misalignment 
events usually occur at highly repetitive, low complexity regions causing some indels to 
be placed inconsistently. The indel realigner in GATK(McKenna, et al., 2010) locally 
realigns these indels such that all indels within a certain genomic region are mapped to 
the same loci. 
Base Recalibration: The phred quality score associated with each base is recalibrated 
using GATK(McKenna, et al., 2010) taking into account the read cycle, the lane, the tile 
and the preceding base of the base to be recalibrated. 
Variant Calling and Annotation: Single nucleotide somatic substitutions were detected 
with MuTect (Cibulskis, et al., 2013) followed by additional filtering of coverage of at 
least 10 reads and Variant Allele Frequency of at least 0.25 (Fig. 5). Short indels were 
called using Samtools(Li, et al., 2009) and GATK Unified Genotyper(McKenna, et al., 
2010). Variants called by Samtools were then filtered using a depth cutoff of at least 10 
reads and quality score of at least 30. Variants called by Samtools are also filtered for 
those variants, which are not present on sequenced reads in both directions. Indels 
identified using Unified Genotyper are filtered for those calls which have a Phred-scaled 
confidence threshold of less than (stand_call_conf) 50. Quality by depth filter of less than 
2 (QD<2), Fisher-Strand bias of greater than 200 (FS>200) and Z-score using a Wilcoxin 
rank sum test of Alt vs Reference allele of less than –20 (ReadPosRankSumTes<-20). 
Subsequently, only those Indels called by both Samtools and GATK after the above 
filtering steps were included for further analysis. Indels were also filtered for those loci  
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involving homopolymer repeats of 5 or more bases and dinucleotide repeats of 10 or 
more bases. 
 
Figure 5: Shows that a minor allele frequency threshold of greater 0.25 greatly reduces 
the number of false positives by taking the known mutations as a truth set. 
 
All variants called were restricted to 25 bp padded exons defined by Refseq or 
Gencode that are targeted by Agilent SureSelect V4 + UTR kit (Fig. 6;Fig. 7). Known 
germline mutations from 1000 genomes project, dbSNP, ESP6500(Consortium, 2010; 
Server and NHLBI, 2012; Sherry, et al., 2001) and an internal variant database having a 
global minor allele frequency of at 0.1% in each were excluded. 
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Figure 6:Shown in red is the called region. Variants were excluded if they the exome 
target regions are not overlapping with REFSEQ and GENCODE defined regions. 
 
 
Figure 7:Shows an example of how we were able to exclude a lot of false positives by 
including only those variants in the capture target space overlapping with known coding 
exons. 
 
 Further, all variants were annotated with snpEff(Cingolani, et al., 2012) using the 
canonical transcripts in the Ensembl 70 database. Annotation of functional predictions of 
the variants was done using SnpSift from dbNSFP(Liu, et al., 2013).  
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Figure 8: Shows the high level overview of the pipeline for mutation calling. 
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5.2.8. CCLE mutations comparison: 25 commercially available cell lines sequenced as 
part of the myeloma cell lines characterization project were also sequenced as part of the 
Cancer Cell Line Encyclopedia (CCLE). We compared the SNV concordance rates for 
these two by applying the same filtering steps as outlined above (Fig. 9). Comparison was 
limited to the 1650 gene panel region resequenced as part of CCLE that also overlapped 
with the SureSelect V4 + UTR target regions. Of the mutations that were identified 
uniquely in CCLE, we looked for evidence of these mutations in the unfiltered call set of 
HMCL and filtered them if present. A similar filtering was applied the uniquely called 
mutations in the HMCL. After these steps, there were a total of 1270 mutations in all. 958 
of these were identified in both projects while 81 were unique to the CCLE cohort while 
231 were unique to the HMCL cohort. 
 
 
Figure 9:Shows the SNV concordance of the mutations called in CCLE and HMCL. 
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5.2.9. aCGH data processing pipeline:  
Agilent feature extraction was used to process microarray images to obtain feature 
intensities and ratios. GC correction, fuzzy zero, centralization and replicate probe 
averaging was applied using Agilent genomic work bench. Copy number segments were 
identified using the Circular Binary Segmentation (CBS) algorithm using the R package 
DNACopy(Seshan and Olshen, 2011). The minimum number of probes required to define 
a segment for cell lines and patients was 2 probes. The segments identified are shown in 
figure 10. 
 
Figure 10: Shows copy number aberrations across all 69 cell lines 
 
Broad and focal amplifications and deletions across all cell lines and patients were 
obtained using GISTIC 2.0(Mermel, et al., 2011). For GISTIC analysis, an amplification 
was defined as any segment that had a log2 fold change ratio of 0.2 while a deletion was 
defined as log2 fold change value of less than 0.2. A list of germline CNV’s were 
provided to exclude them during analysis. Only those focal amplifications and deletions 
with a confidence level of 0.99 were reported.  
 
  93 
To identify genes that are uniquely amplified or deleted in cell lines or patients, 
we considered all significant aberrations with False Discovery Rate q-value < 0.00001. 
From this gene list identified, we looked for evidence of this gene in patients at less 
stringent False Discovery Rate q-value (q<0.25). Finally, only those genes uniquely 
amplified or deleted were included in the list of unique amplifications and deletions. 
 
5.2.10. Identifying Oncogenes and tumor suppressors through integrative analysis: 
Oncogenes: Oncogenes arise from normal, wild-type genes called proto-oncogenes that 
have accrued an alteration in DNA structure resulting in inappropriate activation of the 
gene(Ringer and Schniper, 2000). Such mutations are called gain-of-function mutations 
as they are associated with increased cell proliferation directly or indirectly(Ringer and 
Schniper, 2000). In most oncogenes characterized to date, somatic mutations do not occur 
randomly but affect only a small number of codons(Thomas, et al., 2007). Hence we 
identified oncogenes as genes involving point mutations that occur across at least 5% 
(n=4) of the cell lines at the same position in the genome or altered the same amino acid 
at a minimum. This is based on somatic SNVs identified from exome sequence data. 
Further, for oncogenes to be cancer causing, it should be over expressed or at a minimum 
clearly expressed. Therefore, the identified oncogenic SNVs are only included if they are 
expressed in the RNA-Seq data. 
Tumor Suppressors: The discovery of genetically dominant oncogenes gave rise to the 
idea that there might be a class of genes that oppose their effect of uncontrolled cell 
proliferation(Sherr, 2004). Tumor suppressors are a class of genes that operate in various 
ways that negatively regulate cell proliferation(Hanahan and Weinberg, 2011).  
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Figure 11: Shows different mechanisms through which bi-allelic inactivations could be 
identified through the available data.(A) Depicts an homozygous deletion event (B) A 
point mutation and a single copy deletion (C) Two mutations (D) A single copy deletion 
and fusion (E) Fusion and a point mutation. 
 
Cancer preventive effects require the presence of only a single functional allele and 
hence, along with other oncogenic alterations, inactivation of both alleles is required for 
tumorigenesis(Comings, 1973; Knudson, 1971). This inactivation process, termed the 
two-hit hypothesis by Alfred Knudson who proposed that the process occurs in two steps 
and tumor development does not begin until “two-hits” occur. Since each allelic loss is 
independent, the mechanism on each copy can be one of: inactivation by a point 
mutation, whole or partial gene deletion, structural rearrangements (inversions, 
translocations), or epigenetic modifications (DNA/Histone modifications) (Knudson, 
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2001). Hence to identify potential tumor suppressors, we focused on genes that showed 
evidence for bi-allelic inactivation in the available data (Fig. 11). To identify tumor 
suppressors all non-synonymous point mutations were used. Fusions and copy number 
variants were obtained through methods previously described. A tumor-suppressor is 
defined through one of the following events in the same sample (Fig. 11):  
A homozygous deletion event (aCGH): A homozygous deletion can be identified by 
aCGH alone. To define a homozygous deletion we obtained segmented copy number 
variants from aCGH as previously described. Homozygous deletions are defined as those 
segments which have log ratio less than -3. Further, only segments involving the CCDS 
defined exons were included. Additional filtering to exclude those regions involving 
germline copy-number variations was also done. Finally, genes overlapping the filtered 
homozygously deleted regions for each sample were then identified using Bedtools.  
A single copy deletion plus a mutation in the same gene (aCGH + Exomes): A 
mutation and a deletion event in a gene is determined from aCGH and SNV’s identified. 
To define a single copy deletion, we obtained segmented copy number variants from 
aCGH as previously described. Single copy deleted regions are identified by identifying 
those segments which have a log ratio between -3 and -0.7. Additional filtering to 
exclude segments involving non-CCDS exons and known germline copy number 
variations was done as previously described. Subsequently, genes overlapping the filtered 
single copy deleted regions for each sample were then identified using bedtools. If a point 
mutation, i.e. a single nucleotide variant or indel is identified in the same sample and 
gene having the single copy deletion, then the gene is identified as a tumor suppressor in 
that particular sample. 
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Two independent mutations in the same gene (Exomes): If two non-synonymous 
mutations point mutations, involving the same gene and same sample, are identified in 
the list of putative somatic variants identified, the gene is flagged as a tumor suppressor 
in that particular sample.  
A fusion and a mutation in the same gene (Exomes + RNA-Seq): Genes, involved in a 
fusion in each cell line are obtained as previously described. If a point mutation also 
exists in the exome sequence data in the gene involved in the fusion, then the gene in that 
particular sample is flagged as tumor suppressor. 
A fusion and a single copy deletion in the same gene (RNA-Seq + aCGH): Similarly, 
single copy deletions and a fusion identified in the same gene through methods 
previously described are defined as tumor suppressors. 
To exclude any false positive oncogenes and tumor suppressors due to germline 
SNP’s not previously reported in databases used for filtering, we curated a list of 
significant genes based on functional predictions. Basically, we included the gene in the 
significant gene list if there exists at least one mutation in it across all 69 cell lines that is 
functionally damaging as defined by dbNSFP(Liu, et al., 2013). A mutation is defined as 
damaging if a mutation has either a SIFT score of less that 0.01, a Polyphen 2 score 
greater than 0.95, LRT score less 0.01, mutation taster score of less than 0.01 or  
mutation assessor score of  greater than 4.0. Subsequently, all oncogenes and tumor 
suppressors identified through integrative analysis were included in the final list of genes 
if they were represented in at least 5% (n=4) of the samples and also present in the 
significant gene list. A high level overview of the integrative analysis is shown in figure 
12. 
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Figure 12: Shows a high-level overview of the integrative analysis using WES, RNA-
Seq and aCGH data. 
 
5.3.Results: 
5.3.1. Integrative Analysis:  
We identified putative oncogenes and tumor suppressors through integrative analysis 
previously described. To identify potential oncogenes we focused on mutations that 
occurred at the same position in the genome or altered the same amino acid at a minimum 
in at least 4 cell lines.  This identified 135 genes including KRAS (n=20) and NRAS 
(n=14) previously seen in myeloma along with novel mutations in MAP3K1, MLL3 and 
PRKDC previously implicated in various other cancers(http://cbio.mskcc.org/tcga-
generanker/index.jsp). 
To identify potential tumor suppressors we focused on genes, which showed bi-
allelic inactivation in four or more samples by either a homozygous deletion event, a 
single copy deletion plus mutation, or two independent mutations in the same cell line. 
This identified 107 genes including TP53, TRAF3, FAM46C and DIS3 as expected along 
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with KDM6A, KDM6B, RB1 and PTPRB which are also reported in other cancers as 
driver events. Probing into these genes previously unreported in myeloma may lead to 
novel findings and improved outcomes. In order to identify the role of these novel genes, 
we applied pathway analysis on these genes using Metacore Genego. In order to not 
confound our analysis, we excluded those genes, which are previously reported in 
Myeloma and other cancers. This revealed that immune response involving lectin induced 
complement pathway and classic complement pathway are potential targets. 
Oncogenes Tumor Suppressors 
AAK1, ACBD3, AFAP1L2, AKAP9, 
ALDH1B1, ALMS1, ALPK2, ANKRD28, 
ANLN, APOBEC3H, AQR, ATAD5, 
BBX, BCLAF1, BMP2K, C21orf58, C4A, 
C7orf50, CDC27, CDK5RAP3, CEP170, 
CEP70, CHD1, CLECL1, CLIC1, CPNE1, 
CREB3L2, CTBS, CTSA, CUL9, 
CYFIP2, DDHD1, DDX54, DENND4B, 
DHRS11, DIXDC1, DNHD1, EIF2AK3, 
EME1, EPDR1, FAM171B, FAM228B, 
FAM48A, FAM58A, FMNL1, HLA-
DRB1, HNRPLL, HOMEZ, HSPBAP1, 
IL32, IQSEC1, ITPKB, ITPR2, KAT6B, 
KDM4A, KIF20B, KRAS, LRRK1, LSR, 
LTBP4, MAGEC1, MAGEF1, MAGI1, 
MAN2B2, MAP1LC3B, MAP3K1, 
MAP3K4, MLL3, MRPS34, NCOR1, 
NCOR2, NLN, NLRC3, NOP9, 
NOTCH2, NRAS, NUP54, OSBPL3, 
PABPC1, PALB2, PCMTD1, PDE4DIP, 
PIEZO1, PILRB, PLBD1, PLCD3, 
PLEKHA2, POLRMT, PPFIBP2, 
PRDM2, PRKD3, PRKDC, PRKRA, 
PRSS16, PRUNE2, RASAL3, RBMX, 
RHPN2, RIN3, RP11-1407O15.2, 
RPS19BP1, RTTN, SAAL1, SARM1, 
SCRN3, SERINC2, SLC35E2, 
SLC38A10, SLC46A1, SMPD1, SRGAP2, 
SYNE3, SYNJ1, TAF4B, TDRD3, 
AC009113.1, ADAMTS8, AKAP12, 
AKD1, AMN, AOAH, AP001468.1, 
B3GNT6, BMP15, C12orf56, C1orf173, 
C5orf60, CACNA1F, CDSN, CLCA4, 
COL4A2-AS2, COL6A5, CRIPAK, 
CSMD1, CTD-2611O12.2, DEFB126, 
DIAPH2, DIS3, DKFZP686J19100, 
DNAH10, DNAH9, DSPP, DYNC2H1, 
EYS, FAM186A, FAM46C, FLG, 
FLJ22184, FMN2, GAS2L1, GOLGA6L2, 
GPR112, GXYLT1, HRC, HRNR, 
HUWE1, IGFN1, IGSF3, IL1RAPL1, 
ITIH5, KCNJ12, KDM6A, KDM6B, 
KIF1A, LAMA2, LPAR6, LRP1B, 
LRRC49, LTB, LYZL2, MAML3, 
MGAM, MUC12, MUC16, MUC2, 
MUC20, MUC21, MUC3A, MUC4, 
MUC5B, MUC6, MXRA5, NINL, 
OR2T27, OR4C5, OR9G1, PCLO, 
PIK3C2G, PKD1L2, PLEC, PLIN4, 
PNLIPRP2, PRB3, PTPRD, RB1, RP11-
108K14.4, RP11-124D2.6, RP11-830F9.6, 
RP1L1, RP3-368B9.1, RPSAP58, 
SGK223, SSPO, STAG2, SYNE1, 
SYNPO2, TAS2R31, TCP10L2, TET2, 
TP53, TRAF3, TTN, UBR4, USP26, 
VSIG10L, ZC3H12B, ZNF384, ZNF480, 
ZNF598, ZNF717, ZNF772, ZNF880  
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TMEM121, TNRC6B, TRIM52, TRIOBP, 
UNC13C, URI1, USP40, WBP7, WDR81, 
WNK1, WWC1, ZCCHC3, ZNF408, 
ZNF579, ZNF626, ZNF681, ZNF687, 
ZNF787, ZNF814, ZP3  
Table 2:Shows list of all oncogenes(n=135) and tumor suppressors(n=107) identified 
through integrated analysis of exomes, RNA-Seq and aCGH. Shows in bold are genes 
identified in other cancer. 
 
5.3.2. Cell lines as in vitro models for patient samples  
Myeloma cell lines are widely used as model systems for discovery and validation. 
However, the histopathological lineage for all myeloma cell lines is not completely 
known. Moreover, the underlying genetic events that drive cancers in each subtype varies 
widely. Hence, identifying cell lines best representative of the patient sample by each 
subtype is critical for discovery of biologically relevant results through cell lines and 
several groups have highlighted this need(Berns and Bowtell, 2012; Vaughan, et al., 
2011). Using gene-expression measurement values obtained from RNA-Seq, we applied 
unsupervised hierarchical clustering based on an independently curated gene list. All cell 
lines and patients clustered onto two completely independent dendrograms as shown in 
Fig 13, suggesting significant differences between Cell lines and Patient samples by 
gene-expression.  
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Figure 13: Unsupervised hierarchical clustering of 700 genes with the highest 
standard deviation suggests significant differences between HMCL and Patient samples. 
 
We then asked the question if these differences in gene expression correspond to 
expression of genes required for cells to grow in lab environment rather than biology that 
drives the tumor. We then used the list of genes corresponding to the PAM probe set 
identified by Zhan et al to define subtypes in MM patients(Zhan, et al., 2006) and applied 
unsupervised hierarchical clustering. We hypothesized that this list of genes is more 
relevant to the underlying biology in MM. We hoped that cell lines and patients most 
similar in their expression patterns of genes relevant to MM biology would cluster 
together. However, barring one cell line, FLAM 76, all cell lines clustered onto an 
independent dendrograms as shown in figure 14.  
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Figure 14: Unsupervised hierarchical clustering of Zhan et al. PAM classifier list of 
genes suggests significant differences between HMCL and Patient samples as seen in 
upper color key. Lower color key shows how samples having t(4;14) rearrangements 
cluster together in cell lines and patients despite differences. 
 
Using clustering approaches using an independently identified gene lists as well 
as Zhan et al’s gene list; we found significant differences in expression patterns between 
patients and cell lines. This suggests that cell lines and patients have very different 
profiles by gene expression. Interestingly, despite these differences, the t(4;14) class as 
defined by its overexpression of FGFR3 or MMSET clustered as a distinct group in both 
cell lines and patients albeit within dendrograms corresponding to cell lines and patients 
respectively. This suggests that this subtype is distinctly different from all other subtypes 
The differences in discordant genetic patterns in cell lines and patients are also 
evident at the broad cytogenetic level. We focused on the focal amplifications and 
deletions identified using GITSIC using patients and cell lines and looked for unique 
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CNAs in cell lines compared to patients. We identified significant deletions involving 
1210 genes and amplifications involving 2854 genes uniquely represented in cell lines. 
These events are shown in figures 15 and 16.  
 
 
Figure 15: (A) Shows significant amplifications in cell lines and (B) patient samples. 
Grey bars across the plot show aberrations in Chr 3, 7 and 15 unique to either patients or 
cell lines 
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Figure 16: (A) Shows significant deletions in cell lines and (B) patient samples. Grey 
bars across the plot show aberrations in Chr 3, 5 and X unique to either patients or cell 
lines 
 
Gross genetic differences between cell lines and patient by copy number and gene 
expression profiles were also previously reported in ovarian cancer, leukemia and 
melanoma(Domcke, et al., 2013; Leupin, et al., 2006; XI, et al., 2008). Despite these 
differences, myeloma cell lines are still widely used today as in vitro models for 
exploring different aspects of the disease and hence, identifying better experiment models 
from HMCL is critical. We identified cell lines best representative of patients based on 
common genetic lesions identified in myeloma which are clinically relevant (Table 3). 
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We identified cell lines for 8 classes, namely, 4p16, 11q13, Hyperdiploid, MAF, NFkB 
and Other.  
Common Lesion Feature 
4p16 
• T(4:14) by FISH 
• WHSC1 Fusion 
• WHSC1 or FGFR3 over-expression 
11q13 • T(11:14) by FISH 
• CCND1 over-expression 
Hyperdiploid • Amplification (log 0.45) in at least 4 chromosomes 
(3, 5, 7, 9, 11, 15, 19, 21) 
MAF • T(14;16) by FISH 
• Overexpression of MAF or MAFB 
NFkB • NFkB Activation through mutations in Pathway 
genes 
Other 
• DIS3 Mutation 
• FAM46C inactivation Class 
• RAS Pathway Mutations 
Table 3: Shows common lesions by which myeloma cells lines were defined. 
 
The 4p16 class is marked by its recurrent rearrangements in chromosome 4 
elevating expression the known oncogenes WHSC1 and FGFR3. So, we defined 4p16 
class as having a known t(4;14) reported by FISH with evidence for the translocation 
through a gene fusion event in RNA-Seq along with outlier expression of either target 
FGFR3 or WHSC1. Similarly, a 11q13 cell line is defined by a known t(11;14) by FISH 
and outlier expression of CCND1. The hyperdiploid class of myeloma marked by 
trisomies of odd number chromosomes and having at least 50 chromosomes overall is 
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defined by identifying amplifications in at least 4 chromosomes in 3,5,7,9,11,15,19 and 
21. Prognostically, aggressive MAF tumor cell lines are defined by having a known 
t(14;16) or t(14;20) by FISH and outlier expression of MAF and MAFB. NFkB pathway 
activation is common in myeloma. The constitutive NF-kB pathway activation is enabled 
through both gain-of-function and loss-of-function events. Hence we identified NFkB 
cell line models based on activations in these genes curated from MSigDB. The “other” 
class includes cell lines with mutations and inactivating events in DIS3 and FAM46C and 
also activating aberrations in the RAS pathway genes. Identifying activating and 
inactivating events in NFkB, RAS pathway’s and DIS3 and FAM46C was done based on 
integrative analysis previously described.  Cell lines by each class are shown in figure 17. 
We hope that through this exercise, the myeloma community would benefit by 
identifying better models to explore a biological question of interest. 
Figure 17: Cell lines classified by common lesions identified in them are shown.  
 
5.3.3. KDM6A deletions over represented in Myeloma Cell Lines 
Next, we focused on focal amplifications and deletions that are highly significant (FDR 
q<0.00001) in cell lines but no evidence for these is found in patients even at a less 
stringent threshold (FDR q<0.25). This identified focal deletions involving 3 genes and 
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amplifications involving 252 genes. Interestingly, through this analysis, KDM6A was 
identified as most significant aberration by p-value (6.31E-11) and deleted in HMCL 
alone. KDM6A inactivation’s were previously reported in Myeloma and is believed to	  
Aberration 
Type 
Chromosome 
arm Co-ordinates Genes Involved 
Deletion Xp11.3 chrX:44703859-45008183  KDM6A/UTX 
Deletion Xq21.33 chrX:95926226-98718843  DIAPH2, RPA4 
Amplification 7q36.3 chr7:111240522-159138663  
252 genes involved. 
Excluded for brevity 
Table 4: Significant copy number aberrations identified uniquely in HMCL 
function as a demethylase for histone H3 lysine 27 (H3K27me) and was independent of 
the subtype of myeloma(Keats; Morgan, et al., 2012; Shammas, et al., 2013). To identify 
genes that are affected by KDM6A, we identified cell lines in which there is an 
inactivation of KDM6A through bi-allelic inactivation through integrative analysis and a 
corresponding loss of expression in RNA-Seq. Since, H3K27me3 is a histone marker for 
a repressed transcriptional state, we hypothesized that KDM6A loss inhibits the 
expression of genes that are usually expressed in KDM6A wild-type cells. We performed 
differential expression testing between KDM6A inactivated and wild-type cell lines using 
Cuffdiff. In order to not confound our analysis due to over expression of IGH target 
genes through @IGH rearrangements, we performed differential expression testing for 
t(14;16) and t(11;14) lines independently with and without KDM6A loss. This identified 
101 differentially expressed genes in t(14;16) lines and 228 genes in t(11;14) lines that 
are significantly differentially expressed (FDR p<0.05).  
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Figure 18: Differential expression testing of cell lines with UTX loss and wild type 
identified Beta-catenin-dependent transcription regulation pathway as a target of UTX. 
Genes identified through differential expression and that mapped onto the pathway are 
shown by red bands beside the respective genes (See Appendix D for figure legend). 
 
Pathway analysis of these genes identified Beta-catenin-dependent transcription 
regulation in colorectal cancer canonical pathway to be significantly affected by these 
genes (Fig. 18). The genes involved in the pathway and identified through differential 
expression testing are S100A4, CD44, LAMC2, FAN1 and NRCAM. Incidentally, Jiang 
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et al also reported KDM6A’s important role of endoderm differentiation through 
H3K27me3 demethylases by modulating the WNT/Beta-catenin pathway(Jiang, et al., 
2013).  
Next, we tried to validate the mechanism of action of KDM6A in the Wnt 
signaling pathway. With prior knowledge that KDM6A is a histone demethylase for 
H3K27me3, we characterized an isogenic cell lines ARD and ARP using ChIP-Seq for 
the H3K27me3 and H3K4me3, a marker for actively transcribed promoters, histone 
markers. ARD and ARP representative of t(14;16) cell line models and are derived from 
the same patient. They can be differentiated by their lack and presence of KDM6A. As 
previously pointed out, pathway and differential expression testing analysis identified 
S100A4 to be differentially expressed in t(14;16) cell lines and part of the Wnt signaling 
pathway. Hence, as per our hypothesis, we expected to see expression of S100A4 gene in 
ARP (KDM6A wild-type) alone and we also expected to see H3K27me3 signal in ARD 
(KDM6A inactivated). Confirming our hypothesis, examination of the ChIP-Seq and 
RNA-Seq data revealed this exact pattern (Fig. 19).  
Since KDM6A loss is more common in cell lines, it suggests that KDM6A 
inactivation might be an aggressive progression event that contributes to extra medullary 
growth of tumors, the source of most cell lines, or that it contributes to tumor growth in a 
laboratory tissue culture environment. Taking these facts together, we believe that 
KDM6A inactivation mechanisms acts synergistically through other known mechanisms 
in myeloma and is likely a progression event in late stage myeloma and confers a growth 
advantage. 
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Figure 19:Shows H3K27me3 marker present in ARD (UTX lost) and H3K4me3 marker 
and the corresponding expression of S100A4 gene in ARP (UTX wild-type).  
 
5.4. Conclusion and Discussion 
By characterizing all myeloma cell lines we expanded the annotation of myeloma 
models, which will benefit many aspects of the community’s effort to understand this 
disease. Through our integrative analysis of 69 HMCL using exome and RNA 
Sequencing and aCGH data, we identified 135 oncogenes and 107 tumor suppressors. 
While NRAS, KRAS, FAM46C, TP53, DIS3 were previously implicated as important to 
somatic neoplasms in Myeloma 50 new oncogenes and 24 tumor suppressors implicated 
as important in other cancers we also identified through our analysis. These genes include 
KDM6B, RB1, MAP3K1, MLL3, PRKDC and PTPRB. It is important to understand if 
oncogenic and tumor suppressor activity is unique in cell lines i.e. it is important for cell 
growth in vitro or implicated as a progression event from myeloma to plasma cell 
leukemia. If identified as a progression event in myeloma, such activity in patients has 
important therapeutic implications.  
 
 
  110 
 Our comparison of copy number and gene expression measurements identified 
significantly different genetic profiles between call lines and patients. Interestingly, 
hierarchical clustering of gene expression data despite the differences identified distinct 
t(4;14) clusters. Further, for the benefit of Myeloma research we have defined cell lines 
best representative of patient subtypes based on common lesions in myeloma. This we 
believe would enable researchers to identify appropriate model systems based on the 
question at hand. Our comparison of patient and cell line copy number profiles identified 
deletions in KDM6A previously implicated as a tumor suppressor demthylase 
(H3K27me3 residue) as over represented in the cell lines.  We also identified Beta-
catenin-dependent transcription regulation pathway as a target for KDM6A.  
Despite these promising findings, additional efforts that increase the scale or 
dimensionality of the data such as whole genome sequencing, whole transcriptome 
sequencing, ChIP-sequencing would facilitate advances and many more novel findings in 
myeloma.  
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CHAPTER 6 
CONCLUSION AND NEXT STEPS 
 
The central dogma of molecular biology states the flow of processes in a cell 
starts from transcription of mRNA to DNA and translation of mRNA to protein. In 
essence, the events occurring in DNA should have a downstream impact in RNA as well 
as the resultant proteins. Integrative analysis of datasets allows replicability of results by 
enabling one to look at aberrant DNA and also its downstream mechanisms. Secondly, 
many mechanisms, such as the function of introns, intergenic regions, non-coding RNA’s 
to name a few are not completely understood today. However, examining data from 
different assays together, we can try to determine the impact of such unknown 
mechanisms on the etiology of the disease. To this end, the studies described in this 
dissertation give examples of ways to obtain and integrate variants from high throughput 
genomic datasets to better understand molecular pathology of multiple myeloma. 
 Each chapter in this study has a conclusion section, which mainly focused on the 
highlighting the implications of such studies. Examples when possible were given 
reiterating the importance of such studies and what real world problems they have solved. 
While some the findings are significant in themselves, they also provide a firm ground 
for generating new hypothesis and build upon these findings. Here, I would like to 
reiterate some of implication of these findings but also draw your attention to the future 
directions of this work. 
In Chapter 2, we showed the utility of snpSniffer in identifying sample mixups in 
large scale longitudinal studies such as the MMRF. Though useful in itself, another 
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mixup event that such comparison of genotypes enables is the sample contamination. 
During library preparation one of the potential errors is mixing samples from two 
individuals as one sample before being sequenced. Identifying such errors is currently 
possible through querying the snpSniffer database by examining the heterozygosity rates. 
Consider a genotype at a single position which is homozygous at a certain position in 
sample S1 and heterozygous in sample S2. Mixing two such samples would result in 
higher heterozygosity rates in such samples with errors compared to normal samples. 
While such events can be currently identified through querying the snpSniffer database, 
including the feature into the tool would increase the utility of the tool.  
In chapter 3, a novel pipeline for discovering variants from NGS data was 
described. NGSPE was instrumental in identifying associative gene in T2D but also in 
identifying germline variants in the MMRF cohort(Huang, et al., 2013). Since publishing 
the tool, numerous improvements in variants calling methods were developed and could 
be incorporated into NGSPE. Another feature that could be incorporated into NGSPE is 
to give users the option of identifying somatic variants leveraging existing tools such as 
MuTect and Strelka(Cibulskis, et al., 2013; Saunders, et al., 2012). Another feature 
enhancement that would increase the appeal for NGSPE for a wider audience is through 
the development of a user interface through which users can interact with NGSPE for 
end-to-end analysis from launching jobs to visualizing variants.  
In chapter 4, we showed numerous events causing Dex resistance and validated 
them through orthogonal approaches. Functional assays should be used confirm the 
aberrations. Additionally, functional assays should be performed to see if aberrations 
identified in the resistant line are in fact affected in the presence of Dex in the drug 
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sensitive line. This would confirm Dex targets and could enable effective treatment in 
Myeloma patients with Dex resistance. 
 Through integrative analysis in chapter 5, we identified numerous novel genes 
which might be implicated in the pathology of MM. The immune response pathways 
identified through novel genes should be functionally validated and their relevance to 
MM should be drawn. These genes could potentially aid myeloma cell lines to grow in a 
dish or could be involved in progression to Plasma Cell Leukemia (PCM). To test this 
hypothesis, occurrence of aberrations of these genes could be examined in other cell line 
models and PCM patients. We also showed the significant differences that exist between 
cell lines and patients including deleterious deletions in KDM6A. We showed that these 
deletions affect the transcription regulation in Wnt signaling pathway through differential 
expression testing. We also showed evidence for differences in histone methylation 
patterns due to KDM6A inactivation through isogenic cell lines ARD and ARP. These 
differences in histone methylation patters need to be ascertained through additional ChIP 
sequencing and analysis of all cell lines that harbor KDM6A deletions along with 
appropriate controls.   
 Lastly, while these methodologies were implemented on datasets in Myeloma, 
application of the same methodologies to other cancer genomic datasets such as the 
TCGA would greatly improve understanding of molecular processes in cancer. 
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APPENDIX A 
LIST OF 437 SNP’S BY GENOMIC CO-ORDINATE FOR SAMPLE 
CONCORDANCE USING SNPSNIFFER 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  125 
1:110466466 1:111489901 1:111895487 1:114515717 1:118068934 
1:152079989 1:152733301 1:153012240 1:154744807 1:162470191 
1:162470503 1:162498599 1:164786245 1:167400191 1:171178257 
1:171178264 1:179520506 1:200521412 1:203055101 1:205312848 
1:206759106 1:206760686 1:20977449 1:218519934 1:242053034 
1:248039713 1:28211384 1:31214971 1:40145297 1:40146417 
1:40147343 1:41204569 1:42880516 1:59249359 1:62456014 
1:86195066 1:9009444 1:9161668 1:9162051 2:102018908 
2:110375025 2:111851499 2:1320143 2:1499899 2:152266473 
2:170099473 2:170403030 2:171073887 2:191301368 2:205912403 
2:206547545 2:228736038 2:229889483 2:238236921 2:239000182 
2:240898578 2:3483205 2:3749156 2:47085398 2:47086112 
2:70676329 2:75113789 2:75115108 2:85570857 2:95535544 
3:101576175 3:109213239 3:113804979 3:118867047 3:121346930 
3:1262474 3:127432887 3:133115340 3:140178485 3:14240501 
3:145788467 3:151011969 3:151546041 3:15492786 3:16974610 
3:176739663 3:179137273 3:183528442 3:183558402 3:183702089 
3:186509517 3:20113830 3:33434831 3:42251263 3:42787469 
3:47282303 3:52720080 3:7620789 3:77696422 3:97806616 
4:100227821 4:103173058 4:103173749 4:103174015 4:123818511 
4:141787969 4:38945463 4:40158464 4:76447270 4:76453850 
4:79443850 4:844035 4:90167506 4:90168572 4:953698 
  126 
4:95586224 4:95588075 5:1051687 5:122727026 5:134783254 
5:13691045 5:140168070 5:140168151 5:140203432 5:140228493 
5:140570472 5:147475386 5:148623217 5:168133829 5:169661994 
5:171481606 5:175307886 5:177683377 5:52248873 5:52248904 
5:52249612 5:52386661 5:52386902 5:52387187 5:6372585 
5:68463014 5:68715310 5:75923285 5:75932965 5:76734084 
5:78074198 5:78074918 5:96254817 5:96370879 6:112423810 
6:11579093 6:12290732 6:123103485 6:126210395 6:135285148 
6:137234970 6:147106841 6:152694184 6:160526911 6:160872786 
6:161137779 6:17834213 6:24667407 6:26598188 6:27326863 
6:31079643 6:31079889 6:31838713 6:32605189 6:33055844 
6:36708821 6:36708917 6:36709065 6:36921693 6:36931162 
6:39041502 6:53363488 6:66112409 7:11581134 7:129771117 
7:156447071 7:156469096 7:156469133 7:156469179 7:156469620 
7:2651639 7:30963309 7:43549041 7:44841249 7:47968927 
7:47971575 7:56008858 7:80303716 7:96810729 8:110253879 
8:11643816 8:117858606 8:125061895 8:135612745 8:139824057 
8:141461185 8:141461266 8:1513697 8:20106380 8:26723049 
8:27925204 8:33370757 8:41121280 8:62576976 8:69020496 
8:97506373 9:104172936 9:104182940 9:110093363 9:111777520 
9:115950706 9:116025024 9:117846570 9:125391409 9:127909069 
9:127952210 9:129453229 9:135102254 9:138905136 9:139099073 
  127 
9:139820856 9:139821051 9:140128085 9:14615935 9:36169598 
9:7076463 9:71688101 9:71689375 9:71690974 9:71691239 
9:71692862 9:74865077 9:74969864 9:87489785 9:94486688 
9:97365642 10:100217972 10:100218195 10:100218382 10:102116311 
10:113916311 10:115348727 10:12209399 10:12211761 10:124610027 
10:128019025 10:133954011 10:24873369 10:26592926 10:28228865 
10:38239843 10:38407519 10:44052903 10:44873995 10:52103707 
10:61716788 10:72513682 11:103780095 11:105484844 11:108239628 
11:116691528 11:125763746 11:125828904 11:128843852 11:16133413 
11:26694979 11:32409625 11:33053107 11:35547418 11:5172398 
11:5373646 11:5617987 11:6652618 11:6739407 11:69468171 
11:76836350 11:9003306 11:9304120 11:93847323 11:94354479 
12:102793569 12:10469025 12:12240199 12:15095558 12:21590557 
12:24963188 12:27788795 12:30823971 12:42840955 12:48133563 
12:48375568 12:5603632 12:6929018 12:69646914 12:75437203 
12:9093001 12:9315209 12:94653227 12:94972290 12:95696420 
12:97346924 12:9747676 13:107821863 13:107822150 13:113699488 
13:25356053 13:28577688 13:41374186 13:49883444 13:95673518 
14:104178445 14:20755287 14:20916958 14:23299135 14:35242828 
14:35871075 14:37147341 14:37148385 14:56765746 14:66209190 
14:68042574 14:77236380 14:77732628 14:80669580 14:91925027 
14:96558235 15:23043896 15:36871957 15:50853571 15:51698922 
  128 
15:53807088 15:55837888 15:62157537 15:71125204 15:74487036 
15:77907145 16:11772087 16:11772601 16:129266 16:1961674 
16:21008690 16:277458 16:3272391 16:66978229 16:83065664 
16:89804336 17:10583714 17:15611495 17:1657899 17:18041507 
17:18872337 17:26674153 17:34842521 17:38855772 17:43340936 
17:46802008 17:47591690 17:49239518 17:64802544 17:71280075 
17:73588067 17:7588680 17:76395421 17:76395430 17:78175483 
17:80709062 17:8648103 18:21739725 18:43429966 18:47352533 
18:56963742 18:722402 18:74691225 19:11326119 19:11832283 
19:15662544 19:15726487 19:2477670 19:2514373 19:35597215 
19:3740658 19:41383799 19:44090195 19:44098963 19:44981883 
19:44983567 19:45323198 19:45912507 19:45971366 19:46734255 
19:4852137 19:48613997 19:49899076 19:50771609 19:52033742 
19:52034940 19:52249672 19:55174213 19:55715319 19:57323016 
19:58200628 19:58790713 19:6677989 19:7684457 20:11905642 
20:17474690 20:18445963 20:257320 20:2621998 20:3231340 
20:52786219 20:5283376 20:5526032 20:5566109 20:57244493 
20:6018711 20:60791404 20:61880169 21:15481365 21:34001496 
21:34730699 21:39764016 21:43256252 21:46641968 21:46934826 
21:47961711 22:17443238 22:21167787 22:25158326 22:31043766 
22:38477930 22:38507985 22:39917861 22:42776609 X:118587003 
X:47444985 X:78426988    
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APPENDIX B 
MYELOMA SUB-LINES FROM THE SAME PATIENT ARE DETECTED AS 
UNEXPECTED MATCHES 
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KMS11_JPN_p3_RNA & KMS11_JCRB_Adh_p9_RNA count=87.0 match=86.0 ratio=0.9885057471264368 
KMS11_JCRB_Adh_p9_RNA & KMS11_JPN_p3_RNA count=87.0 match=86.0 ratio=0.9885057471264368 
MM1S_ATCC_p7_RNA & MM1R_ATCC_p7_RNA count=171.0 match=169.0 ratio=0.9883040935672515 
MM1R_ATCC_p7_RNA & MM1S_ATCC_p7_RNA count=171.0 match=169.0 ratio=0.9883040935672515 
KMS11_JPN_p3_RNA & KMS11_JCRB_Sus_p12_RNA count=87.0 match=85.0 ratio=0.9770114942528736 
KMS11_JCRB_Sus_p12_RNA & KMS11_JPN_p3_RNA count=87.0 match=85.0 ratio=0.9770114942528736 
KMS11_JCRB_Sus_p12_RNA & KMS11_JCRB_Adh_p9_RNA count=182.0 match=177.0 ratio=0.9725274725274725 
KMS11_JCRB_Adh_p9_RNA & KMS11_JCRB_Sus_p12_RNA count=182.0 match=177.0 ratio=0.9725274725274725 
Karpas929_ECACC_p15_RN
A 
& Karpas929_ECACC_p10_RN
A 
count=171.0 match=166.0 ratio=0.9707602339181286 
Karpas929_ECACC_p10_RN
A 
& Karpas929_ECACC_p15_RN
A 
count=171.0 match=166.0 ratio=0.9707602339181286 
RPMI8226_ATCC_p7_RNA & COLO677_DSMZ_p8_RNA count=168.0 match=160.0 ratio=0.9523809523809523 
COLO677_DSMZ_p8_RNA & RPMI8226_ATCC_p7_RNA count=168.0 match=160.0 ratio=0.9523809523809523 
KMS28PE_JCRB_p9_RNA & KMS28BM_JCRB_p9_RNA count=156.0 match=147.0 ratio=0.9423076923076923 
KMS28BM_JCRB_p9_RNA & KMS28PE_JCRB_p9_RNA count=156.0 match=147.0 ratio=0.9423076923076923 
ALMC2_DJ_p11_RNA & ALMC1_DJ_p27_RNA count=173.0 match=159.0 ratio=0.9190751445086706 
ALMC1_DJ_p27_RNA & ALMC2_DJ_p11_RNA count=173.0 match=159.0 ratio=0.9190751445086706 
OPM2_DSMZ_p9_RNA & OPM1_p7_RNA count=152.0 match=134.0 ratio=0.881578947368421 
OPM1_p7_RNA & OPM2_DSMZ_p9_RNA count=152.0 match=134.0 ratio=0.881578947368421 
JIM3_ECACC_p10_RNA & JIM1_ECACC_p11_RNA count=171.0 match=149.0 ratio=0.8713450292397661 
JIM1_ECACC_p11_RNA & JIM3_ECACC_p10_RNA count=171.0 match=149.0 ratio=0.8713450292397661 
KMS12PE_JCRB_p9_RNA & KMS12BM_JCRB_p9_RNA count=152.0 match=132.0 ratio=0.868421052631579 
KMS12BM_JCRB_p9_RNA & KMS12PE_JCRB_p9_RNA count=152.0 match=132.0 ratio=0.868421052631579 
KMS11_JPN_p3_RNA & KMS11_JCRB_Adh_p9_exom
e 
count=79.0 match=79.0 ratio=1.0 
JMW1_PLB_p6_RNA & JMW1_PLB_p33_exome count=186.0 match=184.0 ratio=0.989247311827957 
KMS11_JPN_p3_RNA & KMS11_JCRB_Sus_p12_exo
me 
count=80.0 match=79.0 ratio=0.9875 
JIM3_ECACC_p10_RNA & JIM3_ECACC_p5_exome count=170.0 match=167.0 ratio=0.9823529411764705 
VP6_DJ_p5_RNA & VP6_DJ_p4_exome count=165.0 match=159.0 ratio=0.9636363636363636 
MM1R_ATCC_p7_RNA & MM1R_ATCC_p5_exome count=159.0 match=153.0 ratio=0.9622641509433962 
MM1R_ATCC_p7_RNA & MM1S_ATCC_p5_exome count=156.0 match=150.0 ratio=0.9615384615384616 
RPMI8226_ATCC_p7_RNA & RPMI8226_ATCC_p5_exome count=148.0 match=142.0 ratio=0.9594594594594594 
KMS11_JCRB_Adh_p9_RNA & KMS11_JCRB_Sus_p12_exo
me 
count=164.0 match=157.0 ratio=0.9573170731707317 
COLO677_DSMZ_p8_RNA & RPMI8226_ATCC_p5_exome count=169.0 match=161.0 ratio=0.9526627218934911 
MM1S_ATCC_p7_RNA & MM1R_ATCC_p5_exome count=166.0 match=158.0 ratio=0.9518072289156626 
MM1S_ATCC_p7_RNA & MM1S_ATCC_p5_exome count=162.0 match=154.0 ratio=0.9506172839506173 
JMW1_PLB_p6_RNA & JMW1_PLB_p0_exome count=179.0 match=170.0 ratio=0.9497206703910615 
Karpas417_ECACC_p12_RN
A 
& Karpas417_ECACC_p8_exom
e 
count=157.0 match=149.0 ratio=0.9490445859872612 
KMS11_JCRB_Sus_p12_RNA & KMS11_JCRB_Adh_p9_exom
e 
count=170.0 match=161.0 ratio=0.9470588235294117 
RPMI8226_ATCC_p7_RNA & COLO677_DSMZ_p8_exome count=149.0 match=141.0 ratio=0.9463087248322147 
Karpas929_ECACC_p10_RN
A 
& Karpas929_ECACC_p15_exo
me 
count=149.0 match=141.0 ratio=0.9463087248322147 
ALMC2_DJ_p11_RNA & ALMC1_DJ_p27_exome count=177.0 match=166.0 ratio=0.9378531073446328 
KAS61_DJ_p5_RNA & KAS6.1_DJ_p20_exome count=193.0 match=181.0 ratio=0.9378238341968912 
KMS28PE_JCRB_p9_RNA & KMS28BM_JCRB_p9_exome count=146.0 match=136.0 ratio=0.9315068493150684 
VP6_DJ_p5_RNA & VP6_DJ_p0_exome count=168.0 match=156.0 ratio=0.9285714285714286 
KMS28BM_JCRB_p9_RNA & KMS28PE_JCRB_p9_exome count=151.0 match=140.0 ratio=0.9271523178807947 
OPM2_DSMZ_p9_RNA & OPM1_p7_exome count=144.0 match=132.0 ratio=0.9166666666666666 
KAS61_DJ_p5_RNA & KAS6.1_DJ_p0_exome count=188.0 match=172.0 ratio=0.9148936170212766 
OPM1_p7_RNA & OPM2_DSMZ_p9_exome count=153.0 match=139.0 ratio=0.9084967320261438 
KP6_DJ_p8_RNA & KP6_DJ_p28_exome count=178.0 match=161.0 ratio=0.9044943820224719 
ALMC1_DJ_p27_RNA & ALMC2_DJ_p11_exome count=156.0 match=140.0 ratio=0.8974358974358975 
KMS12BM_JCRB_p9_RNA & KMS12PE_JCRB_p9_exome count=151.0 match=132.0 ratio=0.8741721854304636 
KP6_DJ_p8_RNA & KP6_DJ_p0_exome count=178.0 match=155.0 ratio=0.8707865168539326 
JIM1_ECACC_p11_RNA & JIM3_ECACC_p5_exome count=158.0 match=137.0 ratio=0.8670886075949367 
KMS12PE_JCRB_p9_RNA & KMS12BM_JCRB_p9_exome count=135.0 match=117.0 ratio=0.8666666666666667 
JIM3_ECACC_p10_RNA & JIM1_ECACC_p11_exome count=178.0 match=150.0 ratio=0.8426966292134831 
KMS11_JPN_p3_RNA & KMS11_JCRB_Adh_p9_exom
e 
count=79.0 match=79.0 ratio=1.0 
JMW1_PLB_p6_RNA & JMW1_PLB_p33_exome count=186.0 match=184.0 ratio=0.989247311827957 
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KMS11_JPN_p3_RNA & KMS11_JCRB_Sus_p12_exo
me 
count=80.0 match=79.0 ratio=0.9875 
JIM3_ECACC_p10_RNA & JIM3_ECACC_p5_exome count=170.0 match=167.0 ratio=0.9823529411764705 
VP6_DJ_p5_RNA & VP6_DJ_p4_exome count=165.0 match=159.0 ratio=0.9636363636363636 
MM1R_ATCC_p7_RNA & MM1R_ATCC_p5_exome count=159.0 match=153.0 ratio=0.9622641509433962 
MM1R_ATCC_p7_RNA & MM1S_ATCC_p5_exome count=156.0 match=150.0 ratio=0.9615384615384616 
RPMI8226_ATCC_p7_RNA & RPMI8226_ATCC_p5_exome count=148.0 match=142.0 ratio=0.9594594594594594 
KMS11_JCRB_Adh_p9_RNA & KMS11_JCRB_Sus_p12_exo
me 
count=164.0 match=157.0 ratio=0.9573170731707317 
COLO677_DSMZ_p8_RNA & RPMI8226_ATCC_p5_exome count=169.0 match=161.0 ratio=0.9526627218934911 
MM1S_ATCC_p7_RNA & MM1R_ATCC_p5_exome count=166.0 match=158.0 ratio=0.9518072289156626 
MM1S_ATCC_p7_RNA & MM1S_ATCC_p5_exome count=162.0 match=154.0 ratio=0.9506172839506173 
JMW1_PLB_p6_RNA & JMW1_PLB_p0_exome count=179.0 match=170.0 ratio=0.9497206703910615 
Karpas417_ECACC_p12_RN
A 
& Karpas417_ECACC_p8_exom
e 
count=157.0 match=149.0 ratio=0.9490445859872612 
KMS11_JCRB_Sus_p12_RNA & KMS11_JCRB_Adh_p9_exom
e 
count=170.0 match=161.0 ratio=0.9470588235294117 
RPMI8226_ATCC_p7_RNA & COLO677_DSMZ_p8_exome count=149.0 match=141.0 ratio=0.9463087248322147 
Karpas929_ECACC_p10_RN
A 
& Karpas929_ECACC_p15_exo
me 
count=149.0 match=141.0 ratio=0.9463087248322147 
ALMC2_DJ_p11_RNA & ALMC1_DJ_p27_exome count=177.0 match=166.0 ratio=0.9378531073446328 
KAS61_DJ_p5_RNA & KAS6.1_DJ_p20_exome count=193.0 match=181.0 ratio=0.9378238341968912 
KMS28PE_JCRB_p9_RNA & KMS28BM_JCRB_p9_exome count=146.0 match=136.0 ratio=0.9315068493150684 
VP6_DJ_p5_RNA & VP6_DJ_p0_exome count=168.0 match=156.0 ratio=0.9285714285714286 
KMS28BM_JCRB_p9_RNA & KMS28PE_JCRB_p9_exome count=151.0 match=140.0 ratio=0.9271523178807947 
OPM2_DSMZ_p9_RNA & OPM1_p7_exome count=144.0 match=132.0 ratio=0.9166666666666666 
KAS61_DJ_p5_RNA & KAS6.1_DJ_p0_exome count=188.0 match=172.0 ratio=0.9148936170212766 
OPM1_p7_RNA & OPM2_DSMZ_p9_exome count=153.0 match=139.0 ratio=0.9084967320261438 
KP6_DJ_p8_RNA & KP6_DJ_p28_exome count=178.0 match=161.0 ratio=0.9044943820224719 
ALMC1_DJ_p27_RNA & ALMC2_DJ_p11_exome count=156.0 match=140.0 ratio=0.8974358974358975 
KMS12BM_JCRB_p9_RNA & KMS12PE_JCRB_p9_exome count=151.0 match=132.0 ratio=0.8741721854304636 
KP6_DJ_p8_RNA & KP6_DJ_p0_exome count=178.0 match=155.0 ratio=0.8707865168539326 
JIM1_ECACC_p11_RNA & JIM3_ECACC_p5_exome count=158.0 match=137.0 ratio=0.8670886075949367 
KMS12PE_JCRB_p9_RNA & KMS12BM_JCRB_p9_exome count=135.0 match=117.0 ratio=0.8666666666666667 
JIM3_ECACC_p10_RNA & JIM1_ECACC_p11_exome count=178.0 match=150.0 ratio=0.8426966292134831 
KAS61_DJ_p5_exome & KAS6.1_DJ_p20_exome count=351.0 match=348.0 ratio=0.9914529914529915 
KAS6.1_DJ_p20_exome & KAS61_DJ_p5_exome count=351.0 match=348.0 ratio=0.9914529914529915 
JMW1_PLB_p6_exome & JMW1_PLB_p33_exome count=349.0 match=346.0 ratio=0.9914040114613181 
JMW1_PLB_p33_exome & JMW1_PLB_p6_exome count=349.0 match=346.0 ratio=0.9914040114613181 
MM1S_ATCC_p5_exome & MM1R_ATCC_p5_exome count=345.0 match=342.0 ratio=0.991304347826087 
MM1R_ATCC_p5_exome & MM1S_ATCC_p5_exome count=345.0 match=342.0 ratio=0.991304347826087 
KMS11_JCRB_Sus_p12_exo
me 
& KMS11_JCRB_Adh_p9_exom
e 
count=340.0 match=336.0 ratio=0.9882352941176471 
KMS11_JCRB_Adh_p9_exom
e 
& KMS11_JCRB_Sus_p12_exo
me 
count=340.0 match=336.0 ratio=0.9882352941176471 
KAS6.1_DJ_p20_exome & KAS6.1_DJ_p0_exome count=342.0 match=334.0 ratio=0.9766081871345029 
KAS6.1_DJ_p0_exome & KAS6.1_DJ_p20_exome count=342.0 match=334.0 ratio=0.9766081871345029 
VP6_DJ_p5_exome & VP6_DJ_p4_exome count=336.0 match=328.0 ratio=0.9761904761904762 
VP6_DJ_p4_exome & VP6_DJ_p5_exome count=336.0 match=328.0 ratio=0.9761904761904762 
KAS61_DJ_p5_exome & KAS6.1_DJ_p0_exome count=340.0 match=331.0 ratio=0.9735294117647059 
KAS6.1_DJ_p0_exome & KAS61_DJ_p5_exome count=340.0 match=331.0 ratio=0.9735294117647059 
JMW1_PLB_p6_exome & JMW1_PLB_p0_exome count=340.0 match=330.0 ratio=0.9705882352941176 
JMW1_PLB_p0_exome & JMW1_PLB_p6_exome count=340.0 match=330.0 ratio=0.9705882352941176 
RPMI8226_ATCC_p5_exome & COLO677_DSMZ_p8_exome count=335.0 match=325.0 ratio=0.9701492537313433 
COLO677_DSMZ_p8_exome & RPMI8226_ATCC_p5_exome count=335.0 match=325.0 ratio=0.9701492537313433 
VP6_DJ_p4_exome & VP6_DJ_p0_exome count=324.0 match=314.0 ratio=0.9691358024691358 
VP6_DJ_p0_exome & VP6_DJ_p4_exome count=324.0 match=314.0 ratio=0.9691358024691358 
KP6_DJ_p28_exome & KP6_DJ_p0_exome count=347.0 match=336.0 ratio=0.968299711815562 
KP6_DJ_p0_exome & KP6_DJ_p28_exome count=347.0 match=336.0 ratio=0.968299711815562 
JMW1_PLB_p33_exome & JMW1_PLB_p0_exome count=346.0 match=335.0 ratio=0.9682080924855492 
JMW1_PLB_p0_exome & JMW1_PLB_p33_exome count=346.0 match=335.0 ratio=0.9682080924855492 
KP6_DJ_p8_exome & KP6_DJ_p28_exome count=344.0 match=330.0 ratio=0.9593023255813954 
KP6_DJ_p28_exome & KP6_DJ_p8_exome count=344.0 match=330.0 ratio=0.9593023255813954 
OPM2_DSMZ_p9_exome & OPM1_p7_exome count=332.0 match=318.0 ratio=0.9578313253012049 
OPM1_p7_exome & OPM2_DSMZ_p9_exome count=332.0 match=318.0 ratio=0.9578313253012049 
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VP6_DJ_p5_exome & VP6_DJ_p0_exome count=337.0 match=322.0 ratio=0.9554896142433235 
VP6_DJ_p0_exome & VP6_DJ_p5_exome count=337.0 match=322.0 ratio=0.9554896142433235 
KMS28PE_JCRB_p9_exome & KMS28BM_JCRB_p9_exome count=344.0 match=326.0 ratio=0.9476744186046512 
KMS28BM_JCRB_p9_exome & KMS28PE_JCRB_p9_exome count=344.0 match=326.0 ratio=0.9476744186046512 
ALMC2_DJ_p11_exome & ALMC1_DJ_p27_exome count=334.0 match=316.0 ratio=0.9461077844311377 
ALMC1_DJ_p27_exome & ALMC2_DJ_p11_exome count=334.0 match=316.0 ratio=0.9461077844311377 
KP6_DJ_p8_exome & KP6_DJ_p0_exome count=338.0 match=316.0 ratio=0.9349112426035503 
KP6_DJ_p0_exome & KP6_DJ_p8_exome count=338.0 match=316.0 ratio=0.9349112426035503 
KMS12PE_JCRB_p9_exome & KMS12BM_JCRB_p9_exome count=332.0 match=303.0 ratio=0.9126506024096386 
KMS12BM_JCRB_p9_exome & KMS12PE_JCRB_p9_exome count=332.0 match=303.0 ratio=0.9126506024096386 
JIM3_ECACC_p5_exome & JIM1_ECACC_p11_exome count=333.0 match=292.0 ratio=0.8768768768768769 
JIM1_ECACC_p11_exome & JIM3_ECACC_p5_exome count=333.0 match=292.0 ratio=0.8768768768768769 
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APPENDIX C 
STEPS FOR MUTATION CALLING USING NGSPE 
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Note: In the script below, GATK and Picard are expected to be installed in 
‘~/Downloads’ folder, resources files (human_g1k_v37.fasta, 00-All.vcf) are saved in 
‘PATH_TO/resources’ folder and other files (like raw fasta, output files) were saved in 
‘PATH_TO/’ folder. Users would need to change the paths according to their specific 
computer setup. 
1| Make the BurrowsWheeler Transformed (BWT) Index for the reference genome; 
$bwa index ‐a bwtsw PATH_TO/resources/human_g1k_v37.fasta 
 
2| Align the fq1 file to the reference; 
$bwa aln -t 4 PATH_TO/human_g1k_v37 fasta PATH_TO/01_WES_1.fq.gz > 
PATH_TO\ /01_WES_1.fq.sai 
 
3| Align the fq2 file to the reference; 
$bwa aln -t 4 PATH_TO/resources/human_g1k_v37.fasta 
PATH_TO/01_WES_2.fq.gz > \ PATH_TO/01_WES_2.fq.sai 
 
4| Generate the SAM file;  
$bwa sampe PATH_TO/resources/human_g1k_v37.fasta 
PATH_TO/01_WES_1.fq.sai \ PATH_TO/01_WES_2.fq.sai 
PATH_TO/01_WES_1.fq.gz PATH_TO/01_WES_2.fq.gz >\ 
PATH_TO/01_WES_pe.sam 
 
5| Convert SAM to BAM; 
$java -jar ~/Downloads/picard-tools-1.43/SamFormatConverter.jar INPUT= 
01_WES_pe.sam\ OUTPUT=PATH_TO/01_WES_pe.bam 
VALIDATION_STRINGENCY=LENIENT \ TMP_DIR=/tmp 
6| Sort&index the bam file; 
$java -jar ~/Downloads/picard-tools-1.43/SortSam.jar 
INPUT=PATH_TO/01_WES_pe.bam\ OUTPUT= 
PATH_TO/01_WES_pe.sorted.bam SORT_ORDER=coordinate \ 
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VALIDATION_STRINGENCY=LENIENT TMP_DIR=/tmp 
  $java -jar ~/Downloads/picard-tools-1.43/BuildBamIndex.jar \ 
INPUT=PATH_TO/01_WES_pe.sorted.bam\ 
OUTPUT=PATH_TO/01_WES_pe.sorted.bam.bai 
VALIDATION_STRINGENCY=LENIENT\ TMP_DIR=/tmp  
7| Mark duplicates; 
$java –Xmx2g -jar ~/Downloads/picard-tools-1.43/MarkDuplicates.jar \ 
INPUT=PATH_TO/01_WES_pe.sorted.bam 
OUTPUT=PATH_TO/01_WES_pe.dedup.bam \ 
METRICS_FILE=PATH_TO/01_WES_pe.dedup.metrics 
REMOVE_DUPLICATES=false \ ASSUME_SORTED=true 
VALIDATION_STRINGENCY=LENIENT TMP_DIR=/tmp 
8| Sort&index the bam file after mark duplicates; 
$java -jar ~/Downloads/picard-tools-1.43/SortSam.jar \ 
INPUT=PATH_TO/01_WES_pe.dedup.bam \ 
OUTPUT=PATH_TO/01_WES_pe.dedup.sorted.bam 
SORT_ORDER=coordinate \ VALIDATION_STRINGENCY=LENIENT 
TMP_DIR=/tmp 
  $java -jar ~/Downloads/picard-tools-1.43/BuildBamIndex.jar \ 
INPUT=PATH_TO/01_WES_pe.dedup.sorted.bam \ 
OUTPUT=PATH_TO/01_WES_pe.dedup.sorted.bam.bai \ 
VALIDATION_STRINGENCY=LENIENT TMP_DIR=/tmp 
9| Quality value recalibration (count covariate); 
$java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -R \ 
PATH_TO/resources/human_g1k_v37.fasta -- default_read_group 01_WES\ --
default_platform illumina -B:dbsnp,VCF PATH_TO/resources/00-All.vcf –I\ 
PATH_TO/01_WES_pe.dedup.sorted.bam -T CountCovariates -cov 
ReadGroupcovariate\ –cov QualityScoreCovariate -cov CycleCovariate -cov 
DinucCovariate –recalFile\ PATH_TO/01_WESrecal_data.csv  
10| Recalibrate the BAM file; 
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$java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar –R \ 
PATH_TO/resources/human_g1k_v37.fasta --default_read_group 01_WES\ --
default_platform illumina -I PATH_TO/01_WES_pe.dedup.sorted.bam -T 
TableRecalibration\ --out PATH_TO/01_WES_pe.recalibrated.bam -recalFile 
PATH_TO/01_WESrecal_data.csv 
11| Sort&index the recalibrated BAM file; 
$java -jar ~/Downloads/picard-tools-1.43/SortSam.jar \ 
INPUT=PATH_TO/01_WES_pe.recalibrated.bam \ 
OUTPUT=PATH_TO/01_WES_pe.recalibrated.sorted.bam 
SORT_ORDER=coordinate \ VALIDATION_STRINGENCY=LENIENT 
TMP_DIR=/tmp 
$java -jar ~/Downloads/picard-tools-1.43/BuildBamIndex.jar \ 
INPUT=PATH_TO/01_WES_pe.recalibrated.sorted.bam \ 
OUTPUT=PATH_TO/01_WES_pe.recalibrated.sorted.bam.bai \ 
VALIDATION_STRINGENCY=LENIENT TMP_DIR=/tmp 
12| Detect small suspicious intervals in the alignment which will then be realigned to 
get an optimal result; 
$java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T 
RealignerTargetCreator -I \ PATH_TO/01_WES_pe.recalibrated.sorted.bam -R \ 
PATH_TO/resources/human_g1k_v37.fasta -o 
PATH_TO/01_WESforRealigner.intervals\ -B:dbsnp,VCF 
PATH_TO/resources/00-All.vcf  
13| Obtain a cleaned BAM file on which SNP and indel calling takes place; 
$java -Djava.io.tmpdir=/tmp -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar 
-I \ PATH_TO/01_WES_pe.recalibrated.sorted.bam –R\ 
PATH_TO/resources/human_g1k_v37.fasta -T IndelRealigner –targetIntervals\ 
PATH_TO/01_WESforRealigner.intervals --out 
PATH_TO/01_WES_pe_cleaned.bam\ -B:dbsnp,VCF PATH_TO/resources/00-
All.vcf  
14| Generate raw INDELs calls; 
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$java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T IndelGenotyperV2 -
R \ PATH_TO/resources/human_g1k_v37.fasta -I 
PATH_TO/01_WES_pe_cleaned.bam -o \ PATH_TO/01_WES_pe_indels.vcf -
bed PATH_TO/01_WES_pe.indels.bed -verbose \ 
PATH_TO/01_WES_pe_detailed.output.bed -ws 350 
15| Filter raw indels; 
$perl ~/Downloads/Sting/perl/filterSingleSampleCalls.pl –calls \ 
PATH_TO/01_WES_pe.indels.bed --max_cons_av_mm 3.0 --
max_cons_nqs_av_mm 0.5 --\ mode ANNOTATE > 
PATH_TO/01_WES_pe_indels.filtered.bed 
16| Sort&index the cleaned BAM file first, then add readgroup to the cleaned bam 
(only need to include this step if coverage calculation is necessary); 
 $java -jar ~/Downloads/picard-tools-1.43/SortSam.jar \ 
INPUT=PATH_TO/01_WES_pe_cleaned.bam \ 
OUTPUT=PATH_TO/01_WES_pe_cleaned.sorted.bam 
SORT_ORDER=coordinate \ VALIDATION_STRINGENCY=LENIENT 
TMP_DIR=/tmp 
 $java -jar ~/Downloads/picard-tools-1.43/BuildBamIndex.jar \ 
INPUT=PATH_TO/01_WES_pe_cleaned.sorted.bam \ 
OUTPUT=PATH_TO/01_WES_pe_cleaned.sorted.bam.bai \ 
VALIDATION_STRINGENCY=LENIENT TMP_DIR=/tmp 
$java -jar ~/Downloads/picard-tools-1.43/AddOrReplaceReadGroups.jar I=\ 
PATH_TO/01_WES_pe_cleaned.bam 
O=PATH_TO/01_WES_pe_cleaned.RG.bam \ SORT_ORDER=coordinate 
RGID=01_WES RGLB=01_WES RGPL=illumine\ RGPU=01_WES 
RGSM=WES CREATE_INDEX=True 
17| Caculate the average coverage of the sample; 
$java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -R\ 
PATH_TO/resources/human_g1k_v37.fasta -I 
PATH_TO/01_WES_pe_cleaned.RG.bam -T \ DepthOfCoverage -o 
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PATH_TO/01_WES_pe.depthofcoverage -geneList \ 
PATH_TO/human_refGene.bed -mmq 50 -mbq 20 
18| Making raw SNP callings (could use 01_WES_pe_cleaned.bam to replace 
01_WES_pe_cleaned.RG.bam if didn’t take the coverage calculation step); 
$java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -R\ 
PATH_TO/resources/human_g1k_v37.fasta -T UnifiedGenotyper -I\ 
PATH_TO/01_WES_pe_cleaned.RG.bam -B:dbsnp,VCF 
PATH_TO/resources/00-All.vcf -o \ PATH_TO/01_WES_snps.raw.vcf -
stand_call_conf 50.0 -stand_emit_conf 10.0 –dcov 50  
19| Generate SNP filter; 
$python ~/Downloads/Sting/python/makeIndelMask.py \ 
PATH_TO/01_WES_pe_indels.filtered.bed 10 
PATH_TO/01_WES_pe_indels.mask.bed 
20| Obtain filtered SNP callings; 
$java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T VariantFiltration -R 
\ PATH_TO/resources/human_g1k_v37.fasta -o 
PATH_TO/01_WES_pe_snps.filtered.vcf -\ B:variant,VCF 
PATH_TO/01_WES_snps.raw.vcf -B:mask,Bed\ 
PATH_TO/01_WES_pe_indels.mask.bed --maskName InDel --
clusterWindowSize 10 --\ filterExpression "QUAL < 30.0 || QD < 5.0 || HRun > 5 
|| SB > -0.10" --filterName \ "StandardFilters" --filterExpression "MQ0 >= 4 && 
((1.0 * DP) > 0.1)" --filterName\ "HARD_TO_VALIDATE" 
21| Generate statistics on called SNPs; 
$java -Xmx4g -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T 
VariantEval -R \ PATH_TO/resources/human_g1k_v37.fasta -l INFO -
B:eval,VCF \ PATH_TO/01_WES_pe_snps.filtered.vcf -B:dbsnp,VCF 
PATH_TO/resources/00-All.vcf –o \ 
PATH_TO/01_WES.b37_1kg.qc_check_snps.filtered.eval  
The following steps (22-26) are necessary if you want to recall genotypes for a master 
SNP/INDEL list for multi-samples; 
22| Generate SNPs master list; 
java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T CombineVariants -R 
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\ PATH_TO/resources/human_g1k_v37.fasta -B:01_WES,VCF\ 
PATH_TO/01_WES_pe_snps.filtered.vcf -B:02_WES,VCF\ 
PATH_TO/02_WES_pe_snps.filtered.vcf [repeat until -B:sampleN,VCF 
snp.vcf_file] \ PATH_TO/sampleN.vcf  --sites_only -minimalVCF -o 
PATH_TO/master_snps_list.vcf 
23| Recall genotype for SNPs on the master list, repeat this step for each sample; 
java -Xmx7g -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T 
UnifiedGenotyper -R \ PATH_TO/resources/human_g1k_v37.fasta -I 
PATH_TO/01_WES_pe_cleaned.RG.bam -\ B:alleles,vcf 
PATH_TO/master_snps_list.vcf -gt_mode GENOTYPE_GIVEN_ALLELES -\ 
out_mode EMIT_ALL_SITES -BTI alleles -stand_call_conf 0.0 -glm BOTH -G 
none -nsl > \ PATH_TO/01_WES_snp_geno_on_master_list.vcf 
24| Generate INDELs master list; 
java -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T CombineVariants -R 
\ PATH_TO/resources/human_g1k_v37.fasta -B:01_WES,VCF\ 
PATH_TO/01_WES_pe_indels.filtered.vcf -B:02_WES,VCF\ 
PATH_TO/02_WES_pe_indels.filtered.vcf [repeat until -B:sampleN,VCF 
indels.vcf_file] \ PATH_TO/sampleN.vcf --sites_only -minimalVCF -o 
PATH_TO/master_indels_list.vcf 
25| Recall genotype for INDELs on the master list, repeat this step for each sample; 
java -Xmx7g -jar ~/Downloads/Sting/dist/GenomeAnalysisTK.jar -T 
UnifiedGenotyper -R \ PATH_TO/resources/human_g1k_v37.fasta -I 
PATH_TO/01_WES_pe_cleaned.RG.bam -\ B:alleles,vcf 
PATH_TO/master_indels_list.vcf -gt_mode GENOTYPE_GIVEN_ALLELES -\ 
out_mode EMIT_ALL_SITES -BTI alleles -stand_call_conf 0.0 -glm BOTH -G 
none -nsl > \ PATH_TO/01_WES_indel_geno_on_master_list.vcf 
26| Convert the format from vcf first, then annotate the variants (need to first 
download    hg19_refGene, hg19_refLink to humandb/ by using ANNOVAR); 
$perl convert2annovar.pl PATH_TO/master_snps_list.vcf -format 
vcf4>master_snps_list.anno  
$perl annotate_variation.pl -geneanno PATH_TO/master_snps_list.anno 
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humandb/ 
27|    Generate the variants’ annotation summary by using snpEff; 
 java -Xmx4G -jar snpEff.jar eff -v -i vcf -o vcf hg37.63 
PATH_TO/master_snps_list.vcf >\           AnnotatedSNP_output.vcf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  141 
APPENDIX D 
LEGEND FOR PATHWAY MAP (SOURCE: 
https://portal.genego.com/legends/MetaCoreQuickReferenceGuide.pdf) 
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